eke one year perform
page analyst certif import disclosur
 morgan seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report singl factor
make invest decis
tabl content
sector review life scienc tool space outperform broader
healthcar ytd vs xlv although premium
valuat increasingly-difficult comp macro nois includ rise
fx headwind disrupt potenti tariff biopharma consolid
cap out-performance head year-end despit solid fundament
backdrop across end market clearli investor will pay
premium stabil offer life scienc group remain
attract albeit expens safe context continu volatil seen
healthcar sub-sector includ biotech spec pharma gener
hospit distributor pbm within group diagnost particularli
strong run year follow roch acquisit foundat medicin
fmi flatiron health privat well mygn acquisit counsyl
privat recent benefit manageable/bett understood
pama headwind reimburs advanc ldt shield deep
cut rotat away tool light headwind note
term end market trend remain gener healthi across biopharma
biotech fund remain extrem strong near-record level academ
improv fund environ global industri pmi continu
hover near multi-year high although ou pmi meaning moder
peak level cours tool compani also continu see robust growth
china across board despit difficult comp trade war nois demand
benefit long-term polici tailwind lack meaning local
competit product said note saw signific
follow-through earn despit strong organ growth posit end
market commentari exampl post organ growth yet saw
bare stock reaction begin see initi sign rotat
growth-to-valu broader market in-depth sector view
found accompani outlook slide deck
sector outlook expect organ growth larg mirror
core tool group fundament healthi backdrop across biopharma
industri academ end market china remain region growth
engin major obstacl increasingli difficult comp
importantli believ rel easi case made growth
acceler driven major acquisit ad organ line
full year capit deploy continu
import valu creation lever industri remain larg fragment
also benefit dental spin said despit fundament
continu look healthi given growth-to-valu rotat within broader
market valuat remain at/near high forward ev/ebitda
believ compani discount valuat
could better market downturn long continu execut
turnaround plan biggest risk view fund flow growth
valu equiti asset class spur rise interest rate
escal trade war rhetor result punish tariff life scienc
product broader econom slowdown especi and/or china
top pick agil
resili busi model high recur revenu mix much less cyclic
industri exposur remain attract volatil healthcar tape clear path
toward continu organ acceler margin expans addit
upsid option case growth improv
follow dental spin beyond see upsid potenti turnaround
stori compel valuat includ
syneo health urg investor take advantag
broader downturn add exposur long-term open-end growth stori
includ gh
trade premium valuat light potenti upward revis
rate chang along outlook downgrad
neutral underweight organ growth continu downward
trajectori cc ytd vs cc last year contrast robust result seen
across peer view wat current valuat ntm ebitda
ntm price-to-earnings rich given subpar growth profil low visibl
path sustain reacceler limit room margin expans given
diagnost neutral despit long-term potenti flagship
pheno instrument uptak sinc launch year ago well revenu ramp
significantli weaker origin anticip compani
continu bottleneck hospit budget constraint reagent
rental model roll august address issu seen limit
traction prompt us re-evalu invest thesi lower rate
top pick tool given lead growth profil
reduc cyclic long margin expans runway
mark anoth success year agil compani post
impress core growth well initi guidanc peer
group averag underpin broad-bas strength across end market
bottom line compani also continu deliv stellar result bp
opm expans driven combin gross margin expans healthi
oper leverag look ahead continu like setup given
fundament healthi end market conserv guidanc framework leav
room beat-and-rais quarter growth accret recent acquisit lap
colorado oligo manufactur facil run capit deploy
upsid new repo program factor guidanc stock
recov post-strong result previou weak due china/macro-
relat overhang valuat remain attract current ntm ebitda
line tool averag consid lead top-and bottom-lin growth profil
multipl leg acceler includ intuvo/ultivo product cycl
acceler biopharma momentum aforement nasd facil cell
analysi portfolio expans importantli reduc cyclic post spin
consist deliv core growth last four year recur
revenu view stock top pick within core tool group
guidanc look highli beatabl healthi end market share
call core growth biopharma sale expect
continu lead strength sale prudent expect
grow corpor averag given comp year
year upsid number highli like manag note
chang overal demand despit macro nois food sale
expect return growth temporari headwind year due china
ministri reorgan academ fund environ improv
global includ europ despit polit turmoil consid healthi
end market trend clear sign share gain support recent
biopharma lab survey believ initi guidanc highli conserv
set compani beat rais quarter throughout
beyond lt guidanc core growth also look conserv
light multipl driver acceler growth includ intuvo/ultivo product
cycl acceler momentum biopharma nasd facil cell
analysi portfolio expans accret recent acquisit lap
combin annual sale dd compound-annual-growth-rate
china exposur provid upsid downsid
compani signific china exposur sale main sentiment
overhang much year light on-going trade war
food test headwind actual growth china sale turn
robust dd manag note chang custom behavior
due trade war nois although could pull-forward ahead
tariff look ahead china expect grow hsd hsd-ldd
long-term led biopharma driven local biotech driven
energi independ food environment continu benefit
long-term polici tailwind chines govern also
measur impos tariff life scienc tool import view
agil china exposur resili protect broader macro
nois deceler factor difficult comp
long runway ahead margin expans despit temporari headwind
compani achiev opm expans bp driven scale
leverag well suppli chain effici digit initi
opm expans expect modest due bp impact
adopt new pension account standard net impact
price adjust latest -china tariff list well
near-term dilut nasd facil expans beyond transient
headwind see multipl lever on-going opm expans includ
oper leverag new product accret suppli chain save sg
effici one agil model digit lt guidanc
call core increment opm increment assum
core revenu growth plu increment opm addit revenu beyond
growth translat opm
clearer capit deploy framework provid addit upsid
onboard new cfo bob mcmahon compani taken seri step
provid better clariti around capit deploy framework includ
rais dividend author share repurchas still
leav flexibl primari use cash manag note
number compani revenu privat space also
will consid larger deal right opportun emerg
agil histor strong downstream manufactur applic
recent strateg focus upstream especi fast-
grow drug discoveri area genom cell analysi
addit new head strategi corpor develop track
record also strengthen compani muscl
maintain overweight overal agil continu fire cylind
outgrow broader market look ahead beyond continu
see multipl driver place acceler growth includ intuvo/ultivo
product cycl acceler momentum biopharma combin
conserv guidanc framework leav room beat-and-rais reduc
cyclic growth accret recent acquisit lap capit deploy
upsid new repo program factor guidanc continu like
stori maintain overweight decemb pt
question agil manag
start lt guidanc organ growth obvious
conserv compar growth achiev recent year
includ almost core put last quarter view
like sourc upsid
updat us much pharma busi small molecul vs
larg molecul expect rel growth rate
two segment medium term small molecul side
lc replac cycl
obvious expand biolog exposur oligo
manufactur within nasd besid initi
pursu expand biolog exposur highlight analyst
day workflow improv facilit mass spec adopt among biochemist
solut your develop pipelin cater
much biopharma revenu upstream vs downstream
manufactur what ideal mix your target get
pharma valu chain see addit opportun
particip
china key growth region pharma talk pharma
strategi competit posit china term product
see greatest opportun china pharma end market
 extrem robust sinc last year much would
attribut end market strength vs halo effect intuvo
think cycl sustain strength area
within optimistic/pessimist rel year ago
what expect
your bullish china provid color
underli market driver big current exposur china
big think opportun much visibl
food grow area target end market ultivo
think sustain growth rate broader food test market
see opportun agil much agil outgrow market
feel current competit posit food market
capabl gap your look fill
youv experienc headwind china food ministri reorg
remind us larg food environment busi china
respect what magnitud order push-out what
expect time revers
talk drive toward decentr food test china
big think opportun fast captur
talk specif offer go-to-market initi expand
agil market share academ segment soon expect
initi gener meaning revenu contribut
two year intuvo launch updat us uptak far
expect acceler adopt signific revenu contribut
next year geograph see china first market adopt
intuvo given strong outlook
year sinc launch ultivo adopt
end market see placement far near-term
focu still food environment test market time frame
could instal base tripl quad upgrad
comment competit dynam tripl quad given
see instrument launch routin applic tmo tsq
wat xevo tq-gc launch asm june feel
ultivo competit posit factor expect
ultivo ramp
acg grow nice kind growth trend
see consum vs servic vs lab enterpris solut respect
underli driver
percentag instrument sell come attach agil
servic contract variat instrument type servic
attach rate trend last year improv metric
custom class see greatest opportun
what current penetr rate lab enterpris solut
variat end market much runway penetr
capabl reson custom see
greatest opportun go forward
feel current capabl crosslab compar tmo
pki onesourc differenti crosslab competit
win rate like
patholog lab core market what current market share
clinic patholog lab see opportun penetr
larg cdx busi current talk cdx
strategi major opportun agil market
view competit landscap
youv done seri recent acquisit round portfolio
aati qc lasergen sequenc genohm analyt feel
current portfolio addit capabl gap your
look fill either organ inorgan
regard nasd busi expect revenu contribut
new colorado site drug approval/commerci ramp scenario
assum think upsid downsid
number much current capac spoken remind us
make decis capac expans
oper model capit deploy
guid toward increment opm
highlight main lever on-going margin expans price digit
valu engin procur think phase
initi see greater margin expans opportun specif
expect main use cash character current
 environ see greatest opportun set across
portfolio seller expect still high scarciti valu given
activ peer
expect saw continu improv organ
growth ytd exclud best declin due project lumpi
help strengthen end market move opm expans also
continu show good progress effici gain favor mix
bp expect expans year includ bp fx headwind
overal encourag organ acceler sustain
trend remain key question fy organ guidanc still look
modest impli organ growth look next year although new
product nmr scimax timstof biotyp bologna workflow expect
contribut organ growth moder china revenu
europ revenu well slowdown global semiconductor end
market revenu exposur could cap organ momentum share trade
ntm price-to-earnings ntm ebitda remain neutral look
evid sustain organ acceler market level key
construct outlook
saw continu improv organ growth driven
strengthen end market north america although europ china
moder worth watch deliv organ growth
ytd driven growth bsi led strength dalton
mass spec busi biotyp microbiolog franchis strong
academic/industri materi research demand semiconductor metrolog
soften amidst global capital-expenditure slowdown off-set declin best due
project lumpi lsd expect declin full year
geograph north america main driver growth acceler
saw moder europ msd perhap
surprisingli flat ytd growth china vs dd growth seen peer although
manag remain optimist outlook cite healthi end market demand
strong order book look ahead compani expect anoth sequenti
step-up organ growth support healthi msd-hsd order growth
led north america china although think develop
europ china semiconductor industri remain key variabl watch
project acceler expect start contribut organ growth
beyond margin accret well although specif detail
provid manag note signific progress year high-
growth high-margin product area identifi project acceler
includ proteom phenom ultra-high-field nmr neurosci
expect start meaning growth contribut next year
said high-field nmr face secular headwind strong recent adopt
cryo-em tmo/fei steadili draw structur biolog research
fund away nmr trend expect continu addit
compani still need overcom technic hurdl ghz nmr
origin expect ship year push
margin expans show meaning progress date signific
runway still ahead improv along solid organ growth
result repres anoth strong year margin expans
opm set expand bp even bp fx headwind
despit improv brkr opm continu meaning lag
broader tool group driven structur differ
higher equip mix larger european footprint etc still see signific
opportun narrow gap compani set long-term
target bp annual expans
maintain neutral encourag organ acceler
sustain trend remain key question although new product
nmr scimax timstof biotyp bologna workflow expect contribut
organ growth next year moder china europ slowdown
global semiconductor end market could cap organ momentum
share trade ntm price-to-earnings ntm ebitda look
evid sustain organ acceler market level key
construct outlook maintain neutral rate
decemb pt
question manag
greatest exposur european academ demand univers
perspect give us idea primari driver
cycl european academ demand key
lead indic watch measur health market
outsid intern compani metric keep eye
often talk long-cycl natur european academ market
averag long take order convert revenu
convers time increas decreas past year talk
specif product line longest convers time
one short cycl
start see increas nih fund flow big ticket
purchas activ expect meaning tick push
product expect see biggest increment benefit
alway underrepres biopharma rel peer
talk key initi grow busi
area biopharma valu chain product commonli
util part chain see opportun
done recent acquisit biopharma sierra sensor drug
discoveri jpk biomolecular/cellular microscopi expect
move needl
china busi flat ytd tough comp talk
specif drive perform seen variat
across differ product line end market expect
region product expect main driver region
talk specif china industri exposur
current see market
view signific opportun china brrk
next year
japan seen great recoveri year much region contribut
organ growth outlook next year
talk recent launch avanc nmr system
target custom system big could replac
opportun
remind us mani nmr system field
averag age system age custom gener upgrad
percentag nmr system current cover servic
servic attach rate nmr system trend last coupl
year improv
discuss pipelin next-gen ghz nmr technolog
molecular biolog pathogenesi kind impact could
talk view nmr vs cryo-em cryo-em
consist draw structur biolog research fund away high-field
nmr view long-term structur growth rate nmr
busi drive higher lower
current maldi biotyp instal base split
europ averag asp system
penetr smaller hospit higher initi cost could hurdl
leas instrument capit sale
maldi bioytper term system placement
europ drive penetr rate higher drive
next leg growth
regard recent launch bologna workflow adopt
sinc launch europ what roadmap get fda approv
updat us maldi tissuetyp larg market
opportun could
what rational acquir expand footprint
see key advantag hain portfolio type
revenu synergi expect
seen strong growth semiconductor metrolog tool talk
health semi market sustain growth profil
drive health market
provid updat initi
what current servic attach rate initi work
increas servic growth
best suffer tough comp year expect
integr bruker-ost progress date strateg
rational deal best area continu look build
inorgan
oper model cash flow capit deploy
larg compon price increas vs manufactur save
think gross margin expans
remind us annual target opm expans import
mix achiev goal
percentag revenu servic margin profil
servic compar product sale increas mix
discuss chang made manufactur footprint past
year plan regard manufactur still
opportun shift addit manufactur low cost region
low-hang fruit harvest
ideal long-term oper margin busi
compani benchmark
much opportun see sg line drive oper
margin expans specif initi
 spend level want expect see meaning
talk progress made increas free cash flow
convers largest opportun front
inning regard erp/crm enhancement/optim
think optim capit structur busi
discuss thought capit deploy think
bolt-on vs share repurchas
think potenti impact tax reform
dental spin capit deploy make anoth
saw signific pickup organ growth across platform except dental
steadi sequenti acceler quarter core
core core vs core last year despit continu
dental drag flat ytd pend spin next year significantli improv
remainco growth profil addit robust end market demand led
biopharma show clear sign broad-bas share gain across life
scienc diagnost led cepheid environmental/appli led hach
compani becom increasingli adept use db improv innov
commerci execut move continu drive core opm
expans consist excess bp exclud fx headwind
see long runway ahead improv given youth
portfolio term capit deploy rel quiet
 front due sustain high valuat across life scienc space
meaning acquisit date remain well posit
larger deal strong balanc sheet net leverag plan annual
 deploy market correct could open opportun
put togeth continu view one highest qualiti name
coverag univers demand premium valuat current valuat
line tool averag ntm ebitda consid acceler growth
lead free cash flow convers increas option along
opportun valuat re-rat post dental spin continu view
top pick within core tool group maintain dec pt
end market resili busi continu share gain
drive continu strong organ momentum start life scienc
platform growth stellar core driven
robust end market demand also compani strateg focu specif
high-growth area revenu exposur high-growth biolog
genom portfolio span upstream develop downstream
product geographi china well increas penetr
share gain innov compound-annual-growth-rate past three year
commerci execut provid strong support sustain
momentum turn industri side despit recent macro nois
concern peak industri cycl note dhr industri
exposur post spin-off mostli regul market
food/environment test within life scienc water qualiti within
environmental/appli pall industri manag note
sign slowdown furthermor recur revenu mostli
high captiv consum busi highli resili macro cycl
overal see noth horizon stop strong organ growth
momentum difficult comp pall cepheid hach
dental spin remov major sentiment overhang enhanc
remainco growth profil announc plan spin
dental busi independ publicly-trad compani compet
although base earli spin could come sooner
manag express confid dental busi much
better posit time spin given clear sign end market
stabil na inventori destock moder addit new product
launch spark clear align system launch australia on-going
oper improv given gap organ growth rate dental
lsd rest portfolio msd spin remov
major sentiment overhang stock also improv dhr organ growth
power engin drive upsid especi case market
correct rel quiet front due
sustain high valuat across life scienc space
meaning acquisit date revenu remain well
posit larger deal strong balanc sheet net leverag
plan annual deploy market correct could
open opportun term potenti target possibl exist across
four platform albeit unlik dental ahead spin increas
focu softwar digit capabl would surpris see
someth high-growth bioproduct space sooner rather later post
recent analyst day pall previou analyst day highlight busi
segment right follow-on acquisit
maintain overweight overal continu view one highest
qualiti name coverag univers demand premium valuat
current valuat line tool averag ntm ebitda consid
acceler growth reduc cyclic recur revenu long
incom increas option along opportun valuat
re-rat post dental spin continu view top pick within core
tool group maintain dec pt
question manag
given macro concern help us understand busi today
robust busi much less cyclic today
spin think set next year fundament
continu improv
look closer four platform exclud dental grow msd-
hsd year step organ growth everi quarter
contribut organ acceler year specif market
think gain market share
think longer term growth profil portfolio today
expect moder acceler look ahead
busi track ahead growth target year also
step commerci invest specif area
make invest much revenu upsid expect
invest
highlight key initi allow increas
penetr high-growth end market biolog genom appli gene
therapi geographi china think trajectori
expans exposur high-growth market next
year
feel competit posit pall within bioprocess
see opportun strengthen bioprocess
offer especi upstream area cell cultur media
sciex consist hsd talk primari
driver behind continu solid perform expect
feel sciex posit on-going pipelin migrat
small molecul larg molecul
launch topaz clinic mass spec system year ago traction
far expect market adopt clinic mass spec system
ramp next year view new system come
shown strong earli momentum sinc acquisit give us
updat integr progress key focu area expect
growth acceler feel posit
highlight two recent hematolog product launch call
earli custom feedback like start see chang
custom retent rate win rate import think
term re-acceler growth
chemistri immun assay split
rel growth rate feel like right product line
today given new introduct like siemen atellica abbott alin
take acceler beckman busi back msd growth
cphd perform well sinc acquisit talk
primari driver strong growth weve seen surpris
upside/downsid much new custom acquisit china
contribut strength
talk poc strategi much cphd placement
current hospital/refer lab vs poc set mix chang
sinc acquisit expect chang go forward
key differenti genexpert edg platform compar
poc molecular system abbott aler roch liat
china strong growth driver dx busi repres
major expans opportun fact half china busi today
dx provid color market test area custom
segment drive growth key invest prioriti
market competit landscap china differ develop
market price margin implic expand dx
much impact pama implement seen year
instrument placement reagent price much on-going impact
expect current custom contract roll-forward
see gap diagnost portfolio would like fill
feel gener industri market compar start
percentag busi would estim expos short
product id busi continu see healthi msd growth talk
your see term demand cpg vs industri custom
given half pid exposur industri custom see
cyclic risk
dental saw stabil year north america sell-out data
equip consum improv youv note bulk
distributor destock behind us much longer take fulli get
headwind expect
what take dental consum cycl distributor
still talk on-going consum sourc initi
expect price pressur
beyond end market stabil els target achiev get
busi readi spin-off
invest organ intraor scan digit dentistri clear
align talk strategi market think
competit landscap what dhr edg
see major gap equip portfolio would look fill
made signific progress portfolio suppli chain ration
much opportun gm opm expans
main lever what target opm dental time spin-off
regard long-term target bp core margin expans per year
talk factor get higher end rang
would prevent achiev target
made signific progress date improv opm compani
acquir recent year cphd pll go forward oper
compani think greatest opportun opm
expans key lever
convers remain best-in-class talk littl bit
abl consist drive type convers
target annual capit deploy rel
quiet year acquisit updat deal
pipelin recent market volatil chang dynam size
deal could potenti see next year high valuat
dental spin next year impact leverag metric
factor think around time activ extent
take leverag right strateg deal without affect
except franchis oper best-in-class
manag premium valuat
anoth strong year lc growth ytd
organ fuel continu robust lab momentum lc ytd sustain
china strength mid-teen comp vs initi expect hsd growth
food/retail also recov last year declin lc ytd
busi remain lumpi industri remain mute lc ytd
due difficult comp transient oper disrupt product
inspect facil consolid move strong execut
opm line bp expans expect buy-back program
share repo year result ep growth
ytd look ahead preliminari guidanc also met expect
potenti upsid lab product inspect china despit possibl short-
term volatil industri side overal mtd best-in-class manag
execut support long runway ahead organ growth margin expans
although feel factor also appropri reflect
premium valuat ntm ebitda vs tool averag would
look pull back key construct view stock
china remain cornerston market continu healthi long-term
outlook despit cautiou initi outlook hsd base exceedingli strong
growth last year close china revenu continu sustain
strong momentum year mid-teen ytd particular strength
lab close driven robust activ support
long-term polici tailwind industri growth also healthi hsd vs
comp histor china revenu mix bias toward
industri today mix lab revenu closer compani averag
significantli increas exposur faster-grow market
like food biopharma look ahead manag continu maintain
highly-bullish outlook region long-term call hsd-ldd
overal growth although industri side subject short term
volatil includ dd growth lab hsd-dd growth product
inspect msd-hsd growth industri singl digit growth
preliminari guidanc line expect mtd preliminari
outlook call lc revenu growth line expect
reflect msd-hsd growth lab msd growth industri flat growth
food fx expect headwind lab product inspect
china like sourc upsid term -china tariff
manag expect full-year gross impact
increment compar previou expect assum tariff rate
expand list effect januari partial absorb
mix price effici gain bottom line ep expect
bracket street ep growth expect
weight toward mitig measur off-set tariff impact take time
implement addit greater fx headwind trade disput
resolv tariff get lift next year ep growth could improv
robust margin improv expect continu tariff fx
headwind weigh ep growth next coupl quarter long-term
earn power protect strong oper despit impress progress
date along ocean program signific opportun remain servic
product life-cycle manag includ data analyt servic product
price e-commerc share servic final stern drive continu
improv suppli chain manufactur back offic oper
achiev cost save launch year expect deliv
cost reduct year y/i cost save next year
addit thought pleas see recent analyst day recap
except franchis alway valuat remain stick point
overal mtd best-in-class manag execut support long runway
ahead organ growth margin expans although feel
factor also appropri reflect premium valuat ntm
ebitda vs tool averag would look meaning
pull back key construct view stock accordingli
maintain neutral rate decemb price target
question manag
 remain nice growth region talk end
market drive growth obvious biopharma one area
sustain believ growth
europ bit soft last coupl quarter difficult
comp time posit neg develop
would chang growth outlook region differ end
lab product consist deliv strong growth
primari driver
previous highlight product inspect major area share
gain strong growth pi give us
updat current market share pi runway ahead
geographi present greatest near-term opportun
recent manufactur pmi read continu strong appear
softer europ china expect industri busi
trend differ region year
perspect think global econom cycl
lead indic monitor think relev
busi believ underappreci macroeconom
theme
china emerg market
outlook hsd growth china tough comp
much conservat embed account potenti slowdown
demand china due on-going trade war
continu effort reduc mix china revenu industri
custom give us updat current mix end market
target mix your tri get
china huge market great potenti grow penetr product
inspect one exampl biggest opportun
grow penetr term end market product categori
take realiz opportun
talk long-term strategi expand adjac market
signific opportun
long-term goal term consum mix plan
get biotix see organ inorgan opportun
add consum portfolio
highlight opportun grow servic mix given higher
margin strategi around improv servic attach rate
chang break-fix mindset particular end market geographi
plan focu
see servic area becom competit
oper model cash flow
provid updat field turbo progress product area
market invest area shall expect
near-term benefit
gross margin expans bit light past coupl quarter
mention number factor play includ fx headwind
inflat mix expect factor evolv think
gross margin impact geograph mix
given factor play talk strategi manag
gross margin go forward consid expect full-year gross
margin flat y/i much upward potenti think gross
previous highlight direct sale channel key
competit advantag think strategi go forward
light increas penetr e-commerc broader market
review cost-sav initi sg line expect
flow q/q area make chang
macro environ worsen primari lever
pull ensur bottom line growth remain doubl digit
activ deal front recent talk
current strategi activ current deal funnel tuck-in
make sens product geographi
year signific organ acceler help
combin robust end market demand across da dx grow
exposur high-growth market biopharma food diagnost account
revenu increas traction new product launch last two
year easier comp due third-parti softwar glitch impact pki
current organ growth jpme year vs last year quickli
catch higher-growth tool peer like
addit euroimmun organ line next year growth
accret vanadi launch europ genom busi set provid
upsid moreov recent announc addit dr prahlad singh
promot presid diagnost busi previous
serv gener manag effect januari
plan better facilit synergi across busi also
acceler pace innov said current valuat
ntm ebitda alreadi exceed believ
posit larg price leav littl room mistak
compani need deliv heighten expect especi comp
get tougher next year remain neutral view addit evid
sustain euroimmun momentum vanadi traction key
robust end market fuel organ acceler da dx
start da end market strength led biopharma food hsd
academ environment industri market also healthi
although market cyclic product-wis beyond
increas traction new product launch recent year icp-m
food/pharma qsight food test informat onesourc servic
busi also seen mid-teen growth underli market grow hsd-ldd
driven increas outsourc turn dx reproduct health slow
msd growth ytd due declin birth rate global although manag
expect busi return hsd growth next year increas penetr
expand menu off-set declin birth rate particularli
china infecti diseas continu benefit strong uptak emerg
market particularli china india euroimmun also continu
see strong momentum dd growth global autoimmun diseas incid
long-term manag remain confid acceler compani
hsd organ growth reflect expect growth
da hsd-ldd growth dx consist core
reproduct health infecti diseas plu accret
euroimmun vanadi nipt genom ad upsid
sustain momentum remain key question remind
euroimmun lead provid autoimmun test
busi grow portfolio infecti diseas revenu
allergi test solut revenu within autoimmun enjoy
market share broad menu next largest competitor high test
perform due custom antigen-antibodi product capabl
key competit advantag sinc acquisit late euroimmun
continu dd growth trajectori cc ytd cc expect full
year although pace moder averag growth five
year pre-acquisit henc rais question around sustain
momentum visibl busi still low especi
sale china addit compani look drive revenu synergi
euroimmun da cross-sel euroimmun product
life scienc market well oper collabor area
immunoassay develop genom autom workflow digit solut
vanadi nipt expect anoth import growth contributor
compani recent receiv ce mark vanadi nipt system offer
accuraci least match significantli lower cost
price less half cost ngs-base test well better
workflow higher throughput share biochemical-bas prenat
screen market still suffer low accuraci need invas
confirmatori test time confid convert signific
portion market vanadi addit opportun expect open
average-risk popul yet reimburs although acog guidelin
expans expect soon compani initi launch system
europ annual test translat revenu opportun
instal ten lab year minim revenu contribut
traction next year key variabl watch long-term compani
also plan bring vanadi like ldt perform
lab china like
opm expans opportun remain signific especi
euroimmun continu below-p opm jpme
year progress core margin expans year exclud nois
euroimmun deal expens higher stock-bas compens fx
headwind continu encourag driven primarili gross margin expans
bp ytd larg volum leverag euroimmun long-term
compani continu target opm doabl
conserv view driven combin gross
margin expans accret higher consum mix lean manufactur
suppli chain increas opex leverag bulk opportun
remain euroimmun opm time acquisit vs dx opm
potenti reach volum leverag
maintain neutral overal pki current organ growth quickli
catch higher-growth tool peer like addit
euroimmun organ line next year vanadi launch europ
genom busi set provid upsid believ posit
larg reflect current valuat ntm ebitda leav
littl room mistak compani need deliv heighten
expect especi comp get tougher next year remain
neutral view addit evid sustain euroimmun momentum
vanadi traction key construct outlook
question manag
portfolio transform perspect feel pki
collect asset today see pki core compet
look build trim
think long-term sustain growth rate current
portfolio da dx respect put guidanc
could better sustain basi
remind us much biopharma exposur today
feel current set offer competit posit
biopharma market differ product offer instrument
consum softwar servic perform respect within market
driver what product commerci strategi
increas share high-growth market
much share revenu profit onesourc repres
primari driver solid growth continu see
current penetr rate instal base much
share overal lab servic market today think past
said penetr top twenti pharma account
much runway
feel current capabl onesourc offer
compar competit specif uniti agil crosslab given
competitor also aggress expand servic offer
area like complianc informat plan sustain
differenti onesourc competit
food focu area food market perform rel
expect think sustain growth rate broader food
test market see opportun much
outgrow market
round end market see industri environment
academ region expect
would character competit dynam appli market lc
ms given see instrument launch market
tmo tsq wat xevo tq-gc launch asm june
well agil ultivo what strategi maintain gain share
analyt instrument market
feel breadth address market within dx today
feel enough runway gain share within exist address
market tri tap new market
newborn screen continu major busi talk
see term birth rate util breadth test
menu region what expect pace menu expans
emerg market like china menu expans take
polici guidelin perspect much room continu menu expans
develop market like
infecti diseas strong growth driver comment
underli market dynam sustain strength
vanadi talk arriv initi price
mention per test million biochem screen test
europ mani think ultim convert vanadi
quickli much share think ultim take global
expect clinic data initi set ten
custom sens think sensit
launch genom busi last year remind us larg
busi today much revenu synergi exist dx busi
achiev much expect achiev come year
expect busi reach break-even point
given ostens crowd sequenc market plenti competit
genom center low-cost emerg market player expect
genom busi accret dilut pki overal margin
scale busi
would ever content partnership like
euroimmun seen compound-annual-growth-rate last five year driven
think make doubl say next year
also make confid low-to-mid teen growth rate
sustain medium-term
talk integr progress far area
dedic effort see opportun
integr synergi would describ current level
visibl euroimmun busi
remind us main competitor euroimmun china
emea euroimmun key competit advantag
three main market euroimmun autoimmun infecti
diseas allergi estim market size market growth
rate primari growth driver opportun
euroimmun medium-term
increas euroimmun presenc key prioriti talk
competit posit euroimmun product
entrench competitor given euroimmun assay
iif elisa-bas vast major market use
autom chemiluminesc immunoassay clia platform plan
upgrad technolog clia
pama factor broader market backdrop look
penetr market
almost half euroimmun revenu china remind us
driven strength compani posit growth
region china push healthcar deliveri lower-ti hospit
price sensit euroimmun sustain futur growth
china achiev without compromis price margin
elabor revenu synergi opportun euroimmun
rest portfolio
next year think larger euroimmun
oper model cash flow
regard target margin expans could
pars rel magnitud differ sourc opportun portfolio
enhanc exposur china india euroimmun
tulip think potenti evolv manufactur
footprint suppli chain much margin expans expect
achiev manufactur footprint suppli chain optim
thought capit deploy post euroimmun
 would character current environ obvious
number peer includ other continu roll asset
well allow win situat like vanadi euroimmun
term futur deal area capabl look build
inorgan appetit regard potenti increas
leverag optim capit structur compani
term portfolio view potenti sell
addit asset realli prioriti moment
best-in-class organ growth defens busi
capit deploy option make compel
seen signific acceler organ growth across four segment
compani set post record organ growth year best-in-class
growth profil across core tool group aid share gain broad-bas
product leadership strong commerci execut well higher exposur
fast-grow market compar peer biopharma academ
exposur look ahead beyond continu healthi end market trend expect
continu deliv above-market growth see clear path outsiz
organ growth beyond aid accret patheon gatan
deal coupl potenti transform
resili macro risk recur revenu continu like set-up
maintain overweight rate decemb pt
stellar organ momentum support broad-bas strength across
end market seen signific acceler organ growth across
four segment lss organ ai organ sd organ
lp organ ytd repres best-in-class growth across core tool
group beyond robust end market demand across biopharma industri
academ clearli outgrow market broad-bas
product leadership continu invest strong commerci
execut benefit scale scope advantag well higher
exposur fast-grow market compar peer biopharma
academ exposur strateg focu structur biolog research
precis medicin light peak-of-the-cycl concern may
post organ growth recent proprietari
biopharma lab survey shed light sustain tmo strong
organ momentum within biopharma end market total revenu
overal compani current model organ growth
easili see scenario better organ doabl given
continu strong end market fundament importantli tmo abil
outpac broader end market growth although acknowledg comp
overal compani becom difficult start organ
china strong momentum expect continu regardless difficult
comp trade war nois region grown organ compound-annual-growth-rate
revenu last year total sale despit recent
trade war nois concern around potenti growth moder manag
remain highly-optimist medium-term growth outlook china
see least dd growth next year underpin long-term
food safeti semiconductor develop
patheon gatan set add accret organ growth
bottom-lin patheon busi expect accret
revenu due account headwind posit grow
msd-hsd next year accret corpor growth revenu synergi
expect achiev cross sell patheon legaci thermo
custom overlap previous expand access tmo corpor
account stronger combin end-to-end valu proposit biolog
custom addit cross-busi collabor opportun
bottom-lin busi track slightli target ep
accret track achiev total synergi
consist revenu synergi flow oper
margin cost synergi term consolid within highli
fragment market manag note organ capac expans
st loui single-us plant expans announc last month
suffici meet near-term demand although compani remain
open acquir capac opportun emerg final
compani provid less color around expect acquisit
gatan complement fei help organ growth
anniversari expect smaller organ growth contribut
acquisit bd advanc bioprocess busi revenu
next year given late octob close
look highli beatabl analyst day earlier year provid
updat long-term target continu call organ
growth revenu appear conserv given
increas exposur higher-growth biopharma market revenu
patheon part organ line manag aim deliv
organ growth level achiev past three year term margin
profil compani continu call bp annual opm expans
period consist bp organ expans
acquisit synergi mainli pthn result expect opm
rang lead ep compound-annual-growth-rate
addit thought analyst day pleas see recap
step capit deploy plan provid upsid
recent introduc signific step-up plan capit deploy
next three year dedic bolt-on
continu look within current share
repurchas dividend mix unchang last year maintain
averag leverag ratio end year see upsid
 given tmo strong track record consolid
maintain overweight given best-in-class organ growth profil room
acceler continu margin expans runway bp annual
target resili macro risk divers platform high consumable/servic
mix capit deploy upsid continu like setup believ
stock demand premium valuat current valuat remain attract
ntm ebitda tool averag
question manag
long-term organ revenu guidanc rang drive
higher end rang convers could drive lower
end rang
expect growth geograph basi longer term
china strong perform compani discuss
latest trend region end market expect end
market beyond
particularli strong biopharma side youv clearli
outgrow broader market besid pthn synergi commerci execut
also attribut big contributor highlight specif thing
your commerci execut front contribut strength
year that differ previou year
within pharma see term demand larg pharma
vs eu larg pharma vs biotech vs etc seen increas
 larg pharma appetit outsourc manufactur post tax reform
within pharma what current exposur larg molecul vs small
molecul drug mix chang last year
expect chang come year
talk scope benefit pharma portfolio extent
downstream manufactur offer benefit share gain
youv highlight precis medicin initi establish
precis medicin center part portfolio benefit
initi signific precis medicin opportun term
expect contribut organ growth
global academ fund environ consist improv
academ revenu grew msd hsd product line
see biggest benefit increas academ spend
take share increment academ spend particularli light
expect cryo-em adopt ramp next year
way gatan acquisit help acceler adopt reach
peak adopt signific cryo-em opportun long term
break exposur within industrial/appli market
latest trend your see growth expect
beyond much cyclic
talk strategi drive deeper penetr appli
clinic market specif market find attract
strateg import market think tmo edg
market compar competitor tradit focus
market
signific clinic mass spec opportun much futur growth
expect drive diagnost busi
area busi anticip largest competit
either technolog price perspect
fei end market exposur chang much sinc acquisit much
youv clearli take share mass spec chromatographi
take share primarili perspect enabl
share gain
pthn contribut revenu synergi much opportun
see revenu synergi side what full revenu synergi
potenti far along process cross-sel pthn tmo
much increment revenu expect st loui pthn
bioprocess site expans
capabl gap pthn your look fill inorgan
view consolid opportun industri
discuss clinic mass spec strategi compar
cascadion compet system like topaz would initi focu
term target applic what expect timelin term menu
lab product servic talk gross margin within
busi strategi improv gross margin in-hous
manufactur product vs distribut other
talk potenti restructur manufactur facil
could provid term increment earn longer term
biggest remain cost synergi opportun pthn/fei
acquisit what expect timelin achiev full run-rat synergi
biggest opm expans opportun next year
lp oper margin longer term
see gap portfolio point area
interest perspect
youv plan capit deploy next year
earmark far year youv rel quiet
front bolt-on acquisit high public market price
impedi get deal done expect someth end
attract end market differenti platform
continu drive robust growth full valuat keep
us sidelin
recent initi coverag twist neutral rate decemb
pt attract synthet biolog industri backdrop driven
rapid growth applic within healthcar industrial/specialti chemic
agricultur research view market leader back strong
technolog leadership differenti core silicon-bas proprietari platform
lower manufactur cost greater effici rel peer
unmatch growth profil multipl avenu continu growth includ
longer term option around dna-bas data storag solut said
stock strong run post-ipo vs xlv see limit upsid
rel rest coverag univers current level prompt us wait
opportunist entri point pleas see recent initi full color
differenti leader dna synthesi rapid end market
growth driven continu adopt synthet biolog synthet
biolog involv rapid engin dna purpos design
biolog compon enabl advanc across broad rang end
market applic includ drug develop via tool
crispr target molecular diagnost within healthcar product
renew chemic nylon rubber fragranc food flavor spider
silk within industri chemic optim nutrit content crop
yield within agricultur sever emerg use case dna-
base digit data storag opportun lie leverag
proprietari silicon-bas technolog strong commerci infrastructur direct
sale complementari e-commerc platform replac exist solut
help expand market differenti silicon-bas platform
enabl superior accuraci industry-lead error rate per bp
scalabl product gene parallel compar standard
product gene
continu rapidli penetr synthet gene market
complementari set synthet gene product classifi clonal non-
clonal gene synthet dna manufactur process produc
either clonal gene gene perfect qualiti non-clon gene gene near-
perfect qualiti place gene vector vehicl carri dna
use custom workflow underpin direct sale e-commerce
channel continu rapidli penetr sub-seg buyer
develop new use synthet dna in-hous manufactur
typic price sensit convert purchas extern driven access
afford high-qual synthet dna twst
platform outshin competit current custom across
agricultur healthcar technolog particular note renew
contract ginkgo biowork march suppli dna base
pair next four year repres annual revenu
provid element stabil synthet dna revenu near term
although also risk given ginkgo current account
twst sale said believ rel stabil suppli
agreement along rapid penetr dna maker buyer
segment via twst differenti valu proposit help attract
non-ginkgo busi effect diversifi client mix drive
revenu clonal/non-clon synthet gene busi
grow three-year compound-annual-growth-rate
recent launch sampl prepar kit gener
sequenc enabl entri high-growth market
target enrich process dna probe bind isol extract specif
segment sampl dna copi uniformli enabl
analysi differenti competitor
compani offer double-strand dna probe perform target enrich
process provid advantag single-strand dna avoid
deamin process interfer detect infrequ gene
mutat furthermor sinc better target extract uniformli
amplifi target segment solut enabl custom perform fewer
sequenc run per sampl without sacrif accuraci save time
money creat comprehens sampl prepar kit
combin dna probe reagent consum necessari
prepar sampl readi sequenc launch exom captur
kit softwar tool custom captur expect near term given solid
earli traction follow recent launch earlier year see
penetr fast-grow sampl prep market via differenti solut
averag term gener revenu grow three-year
compound-annual-growth-rate
final dna data storag repres sourc embed long-term
option model digit data storag use dna concept
recent found increas traction mani technolog compani includ
micron present experi dna digit data
storag medium dna compact univers ever-last
effici potenti dna mean storag greatli surpass
tradit storag media current assign valu data storag
model given size opportun digit data storag
market view sourc embed option longer term
maintain neutral continu view leader
increasingli attract market project robust top-lin growth medium
term upsid current level like conting sustain growth
core platform diversifi client-bas non-ginkgo revenu ramp
favor resolut agil litig court trial date recent set
februari agil grant option amend
complaint discoveri process move forward progress toward meaning
revenu contribut sampl prepar kit oligo pool librari
continu headway dna-bas data storag solut
factor mind maintain neutral rate
question manag
share color end market industri mix see
meaning applic opportun head next year
turn intern market share addit detail plan
scale oper global particular given privat fund
recent receiv establish product facil china updat us
progress asia
roll e-commerc platform earlier year share
color traction see date addit chang
look make current direct sale e-commerc
term on-going litig agil trade secret misappropri
situat current stand updat us timelin
associ cost expect
current split clonal non-clon gene see
trend favor one within clonal gene mix amongst
order transit higher valu
favor margin someth still expect impact
expect oper result
updat us ginkgo biowork suppli agreement much
gene revenu ginkgo current account expect
exist partnership evolv
share thought sampl prepar ramp date post
launch earlier year rel expect outset
current breakdown commerci late valid earli valid
custom think trend custom mix
averag order size next year
share color ramp antibodi biolog
discovery/develop think develop front
go forward particular expect top-line contribut
biopharma custom updat partnership distribut
updat us progress develop dna-bas digit
data storag via intern research effort industri partnership
univers washington
think opex particularli continu scale
think quarterli cash burn
fundament challeng take time address despit
stepped-up capit deploy downgrad
turbul year organ growth continu downward
trajectori cc ytd vs cc last year
contrast robust result seen across peer weak attribut mix
salesforc disrupt macro headwind although posit note compani
significantli step capit deploy announc
buy-back program overal deceler trend organ growth clearli
disappoint see improv transient headwind
fade new product like bio-tof ramp albeit associ margin
pressur stepped-up share buy-back drive upsid ep
long-term fundament challeng slower small-molecul lc
replac cycl weaker competit posit high-end mass spec
remain view current valuat ntm ebitda ntm price-to-earnings
rich given subpar growth profil low visibl path sustain
reacceler limit room margin expans given current industry-
lead opm move neutral underweight
pharma industri tepid attribut macro overhang
pharma total revenu continu deceler two
year robust growth segment ytd vs last
year contrast robust result seen across peer underli end
market grow hsd weak attribut salesforc disrupt
well mix macro headwind includ gst-relat pullback india
headwind slow pharma budget releas albeit
improv expect improv europ
moder start attribut macro uncertainti relat
brexit turkey turn industri total revenu perform
also soft ytd due difficult comp moder china
well ta instrument shipment delay although expect
revers leav government/academ total revenu
lone bright spot ytd driven strength environment research
pharma discoveri off-set weak biomed research look
ahead call temper revenu growth cc vs
previous reflect expect continu weak pharma
industri near-term linger macro soft europ india
off-set improv north america china
see improv transient headwind fade new product
life bio-tof ramp albeit pressur margin although longer-
term fundament challeng remain expect growth modestli
improv transient headwind pharma industri fade recent
tq-gc dart qda liveid renatadx ramp
government/academ continu healthi momentum improv
global fund environ said believ pharma busi need
overcom fundament challeng modestly-slow replac
cycl small molecul lc pharma busi generic/spec pharma
headwind india elsewher grow competit pressur given
wat weaken posit high-end mass spec reveal
biopharma lab survey leav uncertainti around compani
abil reacceler back msd-hsd growth outlin analyst day
last year compani step invest ytd
new product introduct cadenc year bio-tof system
biolog qa/qc also pipelin believ new product cycl take time
develop mention increas competit peer also continu
capit deploy could provid upsid ep top-lin headwind
gate factor take advantag improv access oversea cash
heel tax reform compani announc share buy-back
program plan grow net leverag translat
capit deploy also leav room potenti bolt-on
share buyback signific buy-back program clearli provid
cushion bottom line believ top-lin organ growth remain
import driver sustain long-term ep growth visibl
path reacceler current limit
downgrad underweight overal deceler trend organ growth
clearli disappoint see modest improv
transient headwind fade new product ramp stepped-up share
buy-back drive upsid ep long-term fundament challeng
slower small-molecul lc replac cycl weaker competit
posit high-end mass spec remain view current valuat
ntm ebitda ntm price-to-earnings rich given subpar growth profil
low visibl path sustain reacceler limit room margin
expans move neutral underweight
question manag
call slower-than-expect pharma budget releas especi
gener side explain drove support pick-
view long-term growth rate market
came call acknowledg lose share high
resolut part biomed research market elabor
dynam revers trend
much pharma sale upstream vs downstream applic
growth rate differ segment along valu
chain see signific growth opportun
pipelin shift biolog chang market opportun
plan grow larg molecul exposur feel
current offer biolog custom capabl gap
look fill either organ inorgan
seem discuss grow upstream discoveri
opportun talk posit biotof seem
focus larg molecul qa/qc
china key growth market pharma thank push toward local
gener drug suppli china overal mid-teen
talk china growth strategi competit posit
market initi your pursu benefit disproport
market tailwind
remind us big pharma presenc india
expect market pick expect growth india trend
next sever year primari driver
lc replac cycl lead pharma custom
decid swap current instrument
competit landscap lc given agil
obvious incumb other like thermo shimadzu make
push
uplc adopt vs expect given target new
drug come pipelin percentag increment market
expect adopt uplc vs hplc view competit
what servic attach rate instrument sell pharma
custom trend last five year
increas also view servic offer versu peer like perkin
agil thermo view opportun expand
innov big theme talk area
place increment emphasi
industri appli market account total revenu
sensit busi industri cycl what medium-term outlook
industri end market
estim food test market grow fast
grow therein much driven china view
signific opportun food market
youv recent launch dart qda liveid food test
your also launch gc-m system food test later year
talk opportun size like custom fast
expect revenu ramp
what long-term outlook environment market region
expect main growth driver
what updat view clinic mass spec competitor
alreadi product market topaz cascadion view
near-term opportun well still wait see sign market
turn ta market sub-seg view signific
opportun ta
key new product launch ta start contribut
meaning revenu
term tier price much current ta sale higher-end vs
middle-end product think mix five year
weve seen healthi academ fund environ across europ
china what outlook wat academ segment given histor
lumpi academ busi sustain think
strength seen recent
view signific opportun academ
look gross margin opportun improv
long term current revenu come recur
consum servic softwar opportun expand mix
drive gross margin higher
sort volum growth need drive gross margin leverag
instrument lc ms consum servic respect assum flat
price what view price sustain within instrument
portfolio variat across differ instrument
updat us think around spend balanc
trade-off drive revenu growth drive expens leverag
much oper leverag see sg line
would character current environ
consist commentari focus bolt-on funnel
would character seller expect point cycl
liquid new solid adopt remain earli
follow extrem well-receiv ipo octob initi coverag
gh overweight rate pioneer highli
attract liquid biopsi market gh develop commerci proprietari blood-
base test detect manag cancer clinic
biopharma use-cas attract top-lin growth
profil driven continu traction steadi momentum
biopharma partnership result came better expect
segment well rel clear line-of-sight expand clinic
reimburs first via issuanc medicar ncd follow recent lcd
plan fda submiss along privat payor traction continu
view gh best-in-class asset attract liquid biopsi space furthermor
despit strong run post-ipo gh trade sale still see
upsid current level particularli signific investor enthusiasm around
option repres develop program
increasingli come sharper focu gh peer grail publish earli
data detail invest thesi pleas see recent
liquid biopsi repres fastest-growth vertic cancer diagnost
liquid biopsi repres clinic set alon
adopt still earli inning set grow rapidli due clinic
valid support guidelin increas payor traction research
use driven rapidli grow share targeted/immuno-
therapi drug candid well-fund biopharma oncolog pipelin
gh liquid biopsi market leader clear first-mov advantag gh
leverag differenti proprietari digit sequenc workflow
success commerci two test person therapi select
omni develop two program focus
recurr monitor earli cancer screen importantli fda approv
panel expect pma submiss expect
pave way pan-canc medicar coverag exist
ncd start follow privat payor traction ramp ou
adopt thereaft omni panel like see robust uptak
research set moreov gh also expect data readout
patient non- vs lung evalu nile studi
compar vs tissue-bas test first-lin nsclc set
posit readout support adopt blood first paradigm assum
studi show non-inferior tradit tissu base test
compani develop program aim
recurr monitor screen hold signific long-term upsid
potenti gh two develop program focus recurr monitor
cancer survivor drug develop well expand precis
oncolog use late stage diseas earli cancer detection/pre-canc
screen high-risk individu specif develop
program aim help clinician monitor cancer recurr post-treat
well assist biopharma compani monitor drug effect
adjuv drug develop clinic trial current ruo
expect launch biopharma set clinic version
test expect thereaft develop program focus
earli cancer detect /screen high-risk individu still
develop commerci launch date set yet long-term upsid
modestli captur model lunar
repres scenario analysi
suggest increment revenu opportun ramp
despit use conserv assumpt
expect three-year top-lin compound-annual-growth-rate driven rapid adopt
clinic oncolog healthi biopharma revenu growth light
favor market backdrop grow use comprehens genom profil
liquid biopsi within clinic research end market outlin
believ gh success leverag market-lead posit
first-mov advantag rapidli increas penetr therapeut select
respons monitor use case drive three-year top-lin compound-annual-growth-rate
longer term compani develop pipelin remain pole posit
drive adopt much larger recurr detect cancer screen
market would repres materi upsid current out-year
estim move estim oper profit break-even like
via expand reimburs cogs-reduct initi
continu see upsid despit premium valuat gh
materi outperform xlv post-ipo continu see upsid due
clear line-of-sight expand reimburs embed option
repres lunar well possibl benefit industri
consolid compani clearli superior top-lin growth
profil forecast y/i growth despit minim
lunar contribut rel peer y/i believ valuat
premium justifi continu see upsid current level
question gh manag
estim penetr rate comprehens genom profil
 today assum metastat patient popul
fraction liquid biopsi provid analog figur ou
view key competitor market share
look like today sustain technolog advantag
expect see potenti competitor horizon
roch acquisit foundat medicin flatiron impact
abil compet particularli light fmi launch
liquid biopsi panel impact relationship roch
discuss patent ip relat technolog
certain cancer technolog suffici
think impact util pan-canc screen test exampl
provid updat anticip time around file pma
fda approv
discuss pan-canc ncd posit liquid biopsi repeat test
long take nsclc reimburs operation
exist ncd fda approv place
interact payor far reimburs
gain reimburs polici privat payor lung cancer
impact coverag payment cancer
polici could creat air pocket model like fmi
view omni within portfolio
talk view biopharma partnership integr
busi model think lead indic busi
statu lawsuit foundat medicin
requir achiev blood-first test paradigm nile studi
much market could switch blood vs tissu eventu
data get access part busi
access phenotyp data
think health econom test
plan launch recurr monitor
think size opportun
plan launch earli detect
think size opportun
think intern penetr revenu growth given
amea jv on-going lc-scrum studi reimburs
look like japan ou market go self-pay rout
amea ex-japan europ
discuss relationship particularli light invest
grail
rel slow growth term sampl volum
think key inflect point term top-lin growth
next year
margin improv mainli come oper leverag
low hang fruit term lever pull reduc cog
think build us commerci channel test
volum ramp particularli commun set
futur proof lab term capac
much cash need get profit
would ever consid acquir nich technolog would improv
current test platform acceler develop timelin lunar
sort area would interest
strong fundament inflect end market set
stage out-performance yet
anoth strong year compani benefit robust
novaseq traction addit strong perform benchtop array
portfolio addit end market clearli begin inflect across
nipt cancer includ liquid biopsi rare diseas popul sequenc
consum genom result start year call y/i
growth up forecast novaseq placement
pull-through came intern expect compani forecast
instal year like conserv look ahead expect
initi guid low- mid-teen top-lin growth
jpme growth led continu novaseq ramp multi-year
replac cycl yet approach halfway mark particularli follow recent
launch cycl kit sp flow cell low throughput applic
expect year-end moreov acquisit
announc novemb deal expect close add
complementari long-read capabl platform cement ilmn market
domin move invest helix project
includ invest commerci pipelin might constrain
margin somewhat ramp novaseq util help step
back secular growth driver continu underpin bullish long-term
view market see deep dive liquid biopsi analysi
color ilmn domin posit strong novaseq momentum see
recent survey drive sustain acceler growth see littl
chang favor outlook head despit premium valuat
novaseq momentum remain impress sustain ramp
util indic grow traction stop provid
specif novaseq shipment/ord number manag note call
placement continu ramp sequenti driven capac expans
plan hiseq convers new high-throughput custom third
categori consist upsid surpris sinc launch continu
expect placement perhap importantli associ
consum made record contribut beat record
number even adjust impact chines custom stock
flow cell biggest contributor among high-throughput flow
cell note novaseq consum increas q/q
follow q/q growth although manag
expect provid steadi state util rang flow cell
launch agbt februari continu ramp repres compel
upgrad option hiseq custom includ use rapid-run mode
offer fastest run time novaseq configur run
hour cycl kit exom singl cell applic
requir cycl enabl flow cell market
sp flow cell low-throughput applic expect launch
year end believ two launch fulli round flow cell
portfolio spur novaseq growth forecast
call increment placement annual pull
per box could also prove conserv
multi-year hiseq replac cycl yet approach halfway mark
remain earli stage multi-year ramp novaseq
manag note even halfway mark term upgrad
cycl upcom sp launch import catalyst
adopt among lower throughput custom remain custom
expect convert come year addit purchas first-tim
custom high-throughput market driven research clinic pop-
seq initi among area ad scale keep pace larger
sequencing-intens project saw robust growth
high-throughput consum broad-bas novaseq strength especi
help off-set expect hiseq declin importantli major hiseq
custom ad novaseq increas total consum spend
past manag provid pull-through rang
hiseq famili point refer util expect
trend novaseq ramp
benchtop revenu continu see upsid nextseq
benchtop instrument portfolio saw healthi growth robust
expans nextseq instal base driven mix capac expans
new-to-nextseq custom low-throughput instal base
miseq/miniseq also grew year new-to-sequenc custom
repres shipment also receiv miseq dx regulatori
approv china allow compani sell box hospit
medic institut ivd test nextseq consum revenu
continu come high-end project util rang
miseq miniseq util remain within rang
respect turn iseq began ship late
launch strong start shipment forecast
demand driven exist new-to-ilmn custom
end market commentari suggest healthi momentum head
includ clinic nipt oncolog rugd popseq consum clinic
shipment notabl oncolog nipt continu grow clinic
translat custom repres shipment vs
use immunotherapi discoveri predict biomark
respons emerg area interest sign collabor
msk use wes/wg use tmb addit
healthi academ research fund environ nih budget saw
increas grow focu sequenc project turn
reimburs highlight first-in-class medicar coverag liquid
biopsi assay nsclc along decis reimburs larg
panel stage iv patient nsclc member
addit final price clinic whole genom sequenc
rugd patient turn nipt continu submit new ivd
applic expand geograph opportun veriseq nipt
 averag risk reimburs coverag stand anticip
acog guidelin chang expect drive posit coverag decis
unit aetna near term popul sequenc also continu ramp
particip all-of-u program select three genom center
expect begin gener genom data quarter healthi nevada
project ad anoth particip third phase addit
alreadi includ yale announc plan sequenc exom start
earli nh intend sequenc whole genom next
five year announc complet sequenc genom last week
estonia plan sequenc resid final discuss
consum genom ancestri helix continu signific
driver array busi eventu believ wgs/we
biopharma interest also continu grow see recap visit
regeneron genet center visit color initi
expect array strength continu recent comment
lh notwithstand driven consum biobank demand follow
period lacklust perform array bright spot
last three year made consciou decis invest array
strategi clearli pay dividend seen growth biobank
agricultur importantli dtc market ytd basi
array revenu grew y/i driven strong dtc demand sampl
well global research applic includ genotyp
epigenet consum lead growth array instrument also
saw spike due one larg dtc custom ad capac ahead
holiday season mirror strength instrument consum array
servic also grown ytd acknowledg lh recent
cut guidanc cite volum weak purchas
instrument place lh run sampl
one four unrel factor drive shortfal moreov
strength array instrument revenu bode well volum next
sever quarter one possibl may
unexpect order shortfal follow signific price cut ancestri
also custom although like explan appear
bring volum in-hous away lh moreov
impact heavi year-end promot activ typic seen among
genealog custom also support array growth final note
genealog ancestri first break-out consum
applic continu see rapid uptak area health well
nutrit fit well new geographi south east asia
highlight one exampl beyond consum also larg emerg
price-sensit market agricultur requir low cost per sampl
high throughput genotyp solut expect recent lh
announc modest impact array growth
acquisit add complementari long-read capabl ilmn
somewhat lack alway believ smrt technolog
current form suit number market includ plant anim
genom hla sequenc pathogen detect bacteri sequenc
pend launch earli access expect begin higher-throughput
henc econom enhanc sequel flow cell
increas throughput vs two year ago open clinic opportun
start rugd pharmacogenom combin
grow moreov cash ltm cash
burn clearli benefit access ilmn commerci
channel cash posit launch new platform ilmn
perspect limit success moleculo avantom
well synthet long read collabor deal facilit entri
true long read segment detail current market
expect grow price point decreas exist instal base
sequel legaci rsii transact expect close
assum regulatori approv term next year expect impact
de minimi deal expect close mid-year even
possibl increas opex associ new sequel launch
context base forecast annual sale repres
sale vs opex
vs term potenti dilut
expect lose next year manag plan share
detail later stage
steadi state novaseq util remain import factor stock
out-performance final enter goe without say
robust novaseq momentum placement importantli steadi state pull
rang compani intend reveal point
year remain import factor drive upsid street estim
sustain ilmn premium valuat price-to-earnings
ev/ebitda coupl realist overli conserv initi top-
line growth outlook light novaseq-driven hiseq replac cycl yet
hit halfway mark posit product newsflow confer like
less swing factor bar announc hold potenti
significantli open clinic market via sample-to-answ workflow
materi reduc price point strong interim readout on-going
grail clinic trial year would also needle-mov extent
data suggest grail potenti becom one ilmn
marque custom road taken togeth model top line
growth along adjust ep exclud impact
step back secular growth driver underpin bullish longer-
term view broader market remain much intact ilmn
domin competit posit particularli light novaseq ramp
pend acquisit reiter overweight rate
head
question manag
call despit beat didnt rais guidanc blame china
stock impact sequenc consum fulli behind
could see dynam continu
call note yet get halfway mark term
hiseq replac cycl give us sens novaseq penetr
rate among hiseq user base custom box
well among legaci hiseq user site box
coupl year launch replac ratio look like within
set
earli custom feedback nih budget increas could drive
bolu instrument purchas
light move part walk us build
novaseq instal expect would drive upside/downsid
turn launch cycl kit launch sp flow cell
expect ye much uptick novaseq demand expect
launch
expect posit give us color annual
pull novaseq start look like moment
turn hiseq hiseq expect consum util
tail possibl pre-valid workflow might increas
longev platform drive inertia term novaseq demand
turn benchtop see miseq term overal
benchtop portfolio expect see platform get cannib
time nextseq miniseq
new sequenc custom drove miniseq miseq demand
go target effect
chang incent structur sale forc term make sure
give us updat earli traction iseq use case
current drive purchas start take share qpcr qc
purpos run
see qgen generead launch begin eat benchtop
order book elong tenders/rfp particularli europ
part goal democrat sequenc touch upon
flexibl sell model offer see evolv
informat space seem gotten get increasingli crowd
last coupl year differenti basespac offer
someth like qiagen clinic insight offer fabric omicia
next step term move toward embed softwar
drive greater adopt importantli monet
relat note sequenc queri often seem gain increas
traction lab focus broader panel period re-analysi
data knowledg evolv thought term
translat demand consum road
updat view potenti disrupt low
cost nanopore-bas sequenc technolog light minion roll-out
potenti ramp promethion gridion
begin see custom use synthet long-read substitut
genuin long read technolog
note drove pull trigger acquisit
point line sight improv throughput follow
launch next year price platinum grade genom
hundr dollar sv analysi new use case could enabl
time-frame see long read market expand beyond
nich spoken
price custom want long read put anoth way
cannibalist portion short read revenu launch
handicap odd regulatori approv
transact geographi need seek approv light
revenu threshold place within market trigger
thought nstg hyb seq sequenc program
bgi claim offer wg data par
although traction remain limit earli stage competitor
take app revenu iphon platform could illumina
ultim take similar cut app develop around
platform
coupl year introduct surpris adopt
rate earli use case theragnost monitor drug resist clinic
expect see secular shift tissu liquid biopsi time
upsid instrument consum sale grail
market rate greater control stake could potenti
worth lot longer term relat note futur proof grail
term instrument purchas next coupl year
price point view realist liquid biopsi base screen
 confid remain payor begin cover
nipt averag risk women even old languag drop
acog yet replac support languag someth expect
happen coupl month ago think hold
long take remain payor follow suit
given rel low price point coverag drive inflect point
revenu volum
outsid ce mark veriseq nipt solut
increment reimburs win countri level quickli
expect demand ramp come year
thought ramp popul sequenc program
one see ramp meaning revenu sourc near
term like long-term opportun
 complet sequenc genom could air
pocket term servic revenu expand program
genom five year ramp see impact brexit nois
decis timelin operation initi
expect meaning revenu contribut yale
nevada all-of-u program
hear china term pop-seq effort much
increment purchas novaseq could drive
note demand consum market drive array
growth driven uptick mostli ancestri sustain
head
light lh recent guidanc cut due soft dtc volum among
reason take happen expect see
impact array sale next coupl quarter promot
price gotten aggress market
think agricultur market volum grown
significantli price remain weak
within consum end market describ see term
emerg use case beyond patern ancestri possibl
geograph highlight array purchas south east asia
call see volum start ramp ou well
littl evid far dtc test result drive lifestyl chang
consum done assess gaug
helix risk end hook cost
sequenc consum make suffici follow-up purchas
cours time manag risk within helix model
oper model cash flow
still view right rang sustain
grow medium term
besid novaseq steadi state util key swing factor
hold potenti impact top-lin perform
move one area focu investor comment
made regard novaseq instrument gross margin
stand today term cut novaseq cog
given consum margin expect differ across platform
busi mix skew toward consum time much
could expand current level next coupl year
anticip increas competit budget pressur reimburs
limit exert downward pressur gross margin longer term
given earli stage adopt curv
think balanc rein oper expens respons top-
line headwind focus drive near-term bottom line growth
share color structur organ current
prioriti give us granular much spend softwar
vs hardwar exampl
think sg next sever quarter novaseq
think impact dilut assum
deal close
longer term oper margin still right way think
anyth bring tax rate time
updat timelin issu new long term target
think stock-bas compens longer term
expect grow line revenu
assum deal close anyth see key gap
portfolio well within market today genet analysi
continu option shift away
ecc model present near-term pocket
continu believ potenti synthet biolog market
xon scalabl busi model encourag increment progress
made healthcar food energi upsid current level like
conting posit late stage clinic data particularli within oncolog along
progress toward meaning revenu contribut energi environment
food aquadvantag salmon launch pend label guidelin
undergo anoth risk assess recent announc well
new late stage collabor sign strateg partnership accompani
disclosur term cash up-front mileston howev note xon
transit away ecc model creat near-term air pocket sinc
xon product yet commerci earli commerci stage lead
risk neg estim revis given near-term risk
well lack clariti around timelin magnitud commercial-scal
transit away ecc model creat air pocket busi
model xon report signific revenu miss recent quarter reflect
strateg decis made last year ramp ecc model product-
driven oper note xon transit away ecc model
creat near-term air pocket sinc xon product yet
commerci earli commerci stage lead risk neg
estim revis said manag continu believ
product-driven oper present compel commerci opportun
go forward though timelin ramp remain larg uncertain
expect next year burden slow recoveri top-line growth
oper initi keep progress modestli analyst day
host ye still tbd relat oper initi xon
continu highlight format actobio subsidiari
xon expect host analyst day date tbd
provid inform portfolio well
candid continu highlight preclin data multigen
therapeut candid suggest potenti superior approv
checkpoint inhibitor actobio xon also announc first
patient dose phase ib/iia clinic trial turn energi sinc
announc overcom technic hurdl isobutanol manag
recent note progress bdo product theoret
final target yield commerci scale facil continu product run
hour plan site select break ground ton
pilot plant compani continu review strategic/financi option
specif product well busi whole global chemic oil
compani view potenti partner within fine chemic xon also
highlight use engin yeast strain produc low cost consist
cannabinoid output via ferment final timelin magnitud
commerci scale adopt around oxitec mosquito control solut combat
zika remain unclear although xon sign second agreement
gate foundat continu make progress gen solut
notabl includ increment mileston tran ova six bull calv born
exemplar genet birth genetically-engin pig potenti human
organ transplant enviroflight plan open largest black soldier fli
facil arctic appl limit commerci launch
manag note expect store along plan
plant anoth tree spring aquadvantag salmon
launch pend label guidelin success feedback new risk
assess recent announc final term ziopharm xon
fulli retir prefer share compani end
maintain neutral encourag increment progress made
healthcar food energi upsid current level like conting
posit late stage clinic data demonstr safeti efficaci
therapeut candid particularli within oncolog along progress
toward meaning revenu contribut energi food environment
asset well new late stage collabor sign strateg partnership
accompani disclosur term cash up-front mileston
question xon manag
briefli describ xon proprietari technolog opportun
current see expans sustain growth
term aquadvantag salmon updat us pend label
guidelin new risk assess conduct launch
competit landscap xon look like viabl
competitor see emerg horizon run
increment competit compani like ginkgo biowork
updat us rational behind statu spin
ahead spin remind us would hard someon
signific budget larg pharma exampl replic
contribut hous term earli product develop
term plan open largest black soldier fli facil
enviroflight give us color develop initi
result mileston hope accomplish
regard exemplar genet announc birth genet
engin pig potenti human organ transplant next
mileston front
talk decis fulli retir prefer share ziopharm
therebi end collabor
second agreement gate foundat progress around
gen solut updat us timelin magnitud
commerci scale adopt around oxitec mosquito control solut combat
plan scale product consumpt aquadvantag
salmon okanagan gm appl abroad plan
undertak public educ market campaign chang neg
percept around gm food especi meat updat us convers
major distributor nation store chain
opportun see product low cost consist
term effort energi remain done term
process regard increas yield convers methan
isobutanol deriv use engin bacteria
turn bdo isbobutyraldehyd mileston expect hit
updat us convers strateg partner energi
asset timelin mind consumm
turn consum give us detail skin hair care
collabor
plan transova go forward
given recent/ongo pilot point expect oxitec zika
mosquito-born diseas solut meaning term commerci
impact take entri sever competitor space
latest term progress intrexon crop protect subsidiari
expect commerci diamondback moth fall
give us glimps deal pipelin mani
convers current on-going potenti partner
particular area interest
oper model cash flow
elabor thought process behind decis
transit ecc-bas busi model product-driven model
updat transit progress
near-term hurdl aros transit away
ecc-bas busi model need overcom plan
tackl issu
anticip signific increas and/or expens near-
term rel last year
would open make signific invest sg drive gm
salmon arctic appl adopt except
gener rule restrict xon involv earli stage develop
comment recent manag chang sylvia wulf
appoint ceo acquabounti etc impact xon
continu mdx momentum offset soft
mix bag core multiplex busi
remain tepid headwind difficult comp labcorp departur
new autom sample-to-answ portfolio continu see strong momentum
ytd although margin profil autom portfolio remain much
lower legaci busi said uncertainti remain new
product traction assay instrument continu stabil consum
sale predict assay demand due flu season evolv
competit landscap reimburs environ stock
ytd trade premium valuat peer ntm ebotda
ntm price-to-earnings feel share fairli valu see limit room multipl
busi remain tepid continu headwind difficult comp
labcorp departur although ytd non-autom system placement
grew y/i nice rebound last year declin due
departur particularli larg custom revenu contribut
modest ytd consum side revenu continu
experi headwind ytd due difficult comp although
recoveri seen meanwhil royalti revenu acceler
growth ytd look ahead expect overal ltg revenu growth next
year similar year jpme potenti acceler
beyond compani aim revamp ltg portfolio sensiplex
new xmap system current develop expect launch
said near-term outlook weigh worse-than-
expect impact labcorp contract departur assay revenu
headwind increment headwind
sample-to-answ portfolio continu track strong stricter panel
reimburs expect help rather hurt revenu sample-
to-answ portfolio ari verigen grew ytd
acceler last year driven mainli strong system placement
ytd total instal base reach custom well
robust util ramp ari menu expans run-rat
significantli year ago verigen util growth
modest run-rat slightli year ago expect
continu strong momentum sample-to-answ portfolio next year
compani target sale despit recent chang outpati
syndrom test reimburs palmetto final lcd weigh
sentiment mdx industri verigen appear better competit
posit given flex price scheme low base price per test less
half price competitor biomerieux/biofir genmark
verigen develop remain track plan launch
remind verigen higher-plex system detect pathogen
hour option verigen compon offer quantit
capabl low- high-plex capabl well faster turnaround
minut compani began clinic trial gi panel june expect
fda submiss late respiratori panel trial
follow upcom flu season follow blood cultur
commerci plan compar compet system
turnaround time verigen current two hour vs one hour qiagen
qiastat system clearli room improv compani indic plan
add real-tim pcr capabl would enabl turnaround
futur upgrad like year
acquisit milliporesigma flow cytometri busi complement
ltg portfolio add balanc growth driver busi expect
gener sale complementari lmnx exist
xmap portfolio end market perspect life scienc research market
less competit mdx market becom increasingly-crowd
new entrant like qiastat system alreadi indirect
exposur end market ltg busi acquisit
millipor flow cytometri busi bring salesforc rep along
intern knowhow test develop allow go market
directli overal flow cytometri market grow fast
account sale acquir portfolio grow dd manag
expect strong ip posit around imag capabl enabl compet
effect larger player like beckman coulter
manag also see sever opportun improv growth margin
profil busi extend portfolio mid-end market
increas recur revenu mix
maintain neutral overal core multiplex busi remain tepid
continu strong momentum new autom sample-to-answ portfolio
help refuel growth although margin profil autom portfolio
remain much lower legaci busi said uncertainti
remain new product traction assay instrument continu stabil
consum sale predict assay demand due flu season
evolv competit landscap reimburs environ
stock ytd trade premium valuat peer ntm
ebotda ntm price-to-earnings feel share fairli valu see limit room
multipl expans keep us neutral
question manag
ltg busi continu see headwind tough comp what
expect growth rate next year
royalti busi remain depend contributor drive
your plan launch new sensiplex system next year
expect new system ramp percentag exist instal base
expect upgrad new system see meaning
opportun grow instal base
what rational acquir flow cytometri busi
milliporesigma acquisit expect contribut exist
busi term competit posit well growth margin
what growth expect flow cytometri portfolio talk
product roadmap expect pivot toward mid-end market
acquir portfolio mostli instrument plan increas
consum either organ inorgan quickli get
industri level consum
acquisit allow take assay develop in-hous go
custom directli implic competit posit
vs exist ltg custom corpor margin profil
sever strong system placement quarter talk
drive
break-out current exposur inpati vs outpati test
mdx would quantifi impact assum broader adopt across
privat payor
talk placement expect ari
think menu expans ari throughout
verigen util growth modest year much runway
think key driver expect util
chang custom util narrow panel expect util
trend verigen launch
expect differ rp vs gi panel given gi higher
outpati mix relax rule larg panel
competitor qiastat also talk flexibl price
expect industri price chang sustain advantag
view current flu trend expect headwind
oper model cash flow
mention consider leverag past
structur chang make realiz leverag
clinic trial new system develop expens
oper cash flow/fre cash flow target longer term
think term share repurchas
think work capit improv next sever
regard much leverag could take right deal
gap portfolio would look build inorgan
pend acquisit illumina keep us neutral
event year seri oper miss
suspend guidanc overshadow propos acquisit offer illumina
earli novemb per share premium then-clos
price cash transact valu compani ev
ttm sale transact expect close time came
somewhat surpris ahead pacb long-await flowcel roll-out
rational appear sound us given ilmn limit success
previously-acquir long read effort avantom moleculo coupl grow
view long-read reveal complementari relev inform ilmn
short-read approach notabl recent progress made increas
throughput drive price key gate factor wider
adopt beyond nich use case well limit resourc success
commerci pipelin like acceler process said
manag directli comment anti-trust concern given ilmn
domin short-read market pacb domin long-read
segment beyond allud limit current overlap use case note
rel long time-frame announc target deal close
reflect regulatori approv need put place due dilig
suggest need seek anti-trust approv china sinc pacb
chines revenu fall regulatori threshold necessit
approv final subsequ proxi reveal identifi
prefer strateg partner chines market discuss regard
simultan invest one/mor chines investor one compani
previous explor partnership express highli
preliminari interest acquir view likelihood compet bid
emerg stage rel unlik light propos
acquisit per share remain neutral head
add complementari long-read capabl ilmn best-in-class
short-read sb portfolio pacb commerci execut
somewhat lack alway believ smrt technolog current
form suit number market includ plant anim genom
hla sequenc pathogen detect bacteri sequenc pend
launch higher-throughput henc econom enhanc sequel
flow cell see detail open clinic opportun start
rugd pharmacogenom combin grow
moreov cash ltm cash burn
clearli benefit access ilmn commerci channel
cash posit launch new platform ilmn perspect
limit success moleculo avantom well
synthet long read collabor deal facilit entri true long read
segment detail current market expect grow
price point decreas exist instal base sequel
impact ilmn manag despit expect dilut
term next year expect impact de minimi
deal expect close even possibl increas
opex associ new sequel launch context base
forecast annual sale repres sale
vs opex vs
term potenti dilut expect lose next
year although manag expect share detail later stage
pacb recent pipelin progress key catalyst purchas
releas earli new chemistri softwar pacb sequel drove
instrument placement well util custom saw clear
improv read length throughput cost save rel legaci
rsii platform softwar improv simplifi sampl prep kit
chemistri releas manag doubl sequel throughput
major chemistri softwar releas increas read length yield along
launch new smrt cell octob ashg provid
next boost perform improv translat per
smrt cell averag read length kb consensu
accuraci wg project look ahead anticip
improv via new smrt cell chip earli develop
track complet ye earli access schedul begin
get throughput target vs two year ago importantli
level throughput enabl sequenc platinum-grad genom
vs current level low-coverag genom structur
variant analysi hundr dollar turn help expand
address market via applic clinic market
along deal also announc result miss consensu
follow string similar miss earlier year along deal
announc releas result revenu come
street due lower instrument shipment consum sale
continu trend seen earlier year note lower
consum sale due lower demand rsii consum variat
custom order pattern anticip new product launch includ
flow cell announc ashg octob new flow cell
significantli yet
maintain neutral rate light propos acquisit
per share remain neutral head
unmatch growth profil promis pipelin keep us
overweight
led experienc manag team board proven track record
commerci disrupt technolog expect captur meaning share
life scienc research space multipl long-term shot goal clinic
market overal set-up look similar earli day sequenc
market believ repres one intrigu small-cap stori
univers see littl chang invest debat compani
unmatch growth profil multipl avenu continu growth includ
simoa planar benchtop system plex capabl manag
expect launch vs previous remain
overweight pleas see initi earlier year full color
unmatch growth profil revenu consist come
estim y/i revenu underpin robust
increas consum y/i servic revenu y/i driven
larg expans biopharma partnership compani
penetr top biopharma compani instrument placement
also remain healthi y/i sr-x book order sinc launch
overal product sale grow y/i pharma y/i
academ busi current oncolog neurolog
combin sector grow y/i constitut big piec
qtrx futur franchis accordingli expect sustain growth go
forward trial public date valid
technolog compani plan underway build distribut channel
asia importantli manag note mark mix shift
consum repres grow stake pave clear path margin
expans long-term
pipelin progress remain strong term pipelin call
manag elabor step taken integr planer
technolog acquir aushon simoa enabl higher-plex test
without compromis sensit compani plan launch simoa
planar benchtop system plex capabl vs previous
previous disclos also gain back unrestrict right simoa
technolog vitro diagnost market termin licens
agreement biomeriex result one-tim contribut
top-line worth note exclud amount revenu growth
remain solid y/i
maintain overweight see littl chang invest debat
compani unmatch growth profil multipl avenu continu
growth includ simoa planar benchtop system plex capabl
manag expect launch thu remain overweight
question manag
given ramp consum expect revenu mix look
go forward impact think mix shift
given sr-x book order sinc launch expect
make sure momentum maintain go
consid expans biopharma partnership on-going
collabor top biopharma compani expect
partnership evolv time hope increas size
deal step take achiev object
given greatest bulk busi compos oncolog
neurolog cumul display meaning growth y/i
expect futur growth deriv segment
plan expand segment well plan
gain back unrestrict right simoa technolog vitro
diagnost market termin licens agreement
biomeriex impact forese unrestrict right
revenu
still expect launch simoa planar benchtop system plex
capabl remind us market opportun benchtop
system mileston hope achiev
along simoa planar benchtop system launch anyth els
pipelin market opportun
public valid technolog portfolio date
point us import recent paper studi still
on-going expect meaning
updat us plan build distribut channel asia
expect timelin associ cost plan scale
busi
think opex particularli keep develop
pipelin simoa planar benchtop system plex capabl
think quarterli cash burn
exactli acceler hope year
string frustrat quarter recent downgrad neutral post
result compani post yet anoth signific top-line miss
revenu consensu despit record-high system placement
continu bottleneck hospit budget constraint reagent rental
model roll august address issu seen limit traction
custom struggl secur budget cycl capit step back
note dilig continu suggest decent custom interest pheno
ramp clearli take longer expect includ unexpect delay
start clinic trial process sever bacteri pneumonia test
share like range-bound pend meaning acceler
pheno ramp success menu expans see better risk/reward part
coverag univers
promis earli traction placement revenu
europ current system contract includ
placement evalu contract europ
drive growth instal base reorgan sale team
manag reduc sale cycl drive growth commerci
placement last quarter recent contract four gpo
cover hospit sign last largest
expedit contract process futur neg reagent
rental model launch toward end assist hospit budget
constraint bottleneck seen develop custom
present score sinc roll-out although traction remain limit due
custom still struggl secur budget cycl capit meanwhil note
long runway lie ahead sepsi market estim test
qualifi prospect account repres instrument
north america alon continu believ offer long-term
opportun pend public data multipl random
prospect clinic trial provid evid clinic
econom benefit pheno includ previously-highlight mayo clinic
ucla independ studi enrol complet among other final
 eu manag note annuiti per system
track expect compani track averag contract
volum per instrument bit lower eu
despit grow instal base long convers cycl remain key
hurdl continu believ progress oper initi coupl
custom interest pheno provid long-term growth opportun
although time ramp remain larg uncertain instal
repres progress revenu extrem light manag
attribut longer-than-expect order convers cycl due extens
custom evalu period addit time custom take post-contract
sign build uniqu li interfac system although
manag note progress month vs month year ago driven
dedic li team improv qc manag hope continu
improv order convers cycl drive rapid penetr
expens short-term revenu reagent rental model
menu expans see addit delay remind also expand
respiratori test complet assay develop kit target
sever pneumonia increas axdx current
test test assum price per test averag
initi compani agre fda pathway sever
pneumonia assay expect lead expedit approv
thu plan begin clinic trial test late earli
call manag note addit delay due fda
pushback tie lack reproduc refer method pre-
clinic data obtain show high variabl quantit cultur
method consequ compani talk fda modifi studi
design produc reproduc refer method look time progress
start clinic trial test process follow enrol site
outcom studi addit data support clinic
econom benefit pheno sever pneumonia case sign meaning
remain neutral step back note dilig continu
suggest decent custom interest pheno ramp clearli take longer
expect share like range-bound pend meaning
acceler pheno ramp success menu expans see better
risk/reward part coverag univers
question manag
updat us progress reagent rental model impact
expect overcom hospit budget constraint
step plan take overcom headwind
percentag system placement expect capit sale
talk view signific unmet need
microbiolog lab acceler pheno design address
mani system expect averag hospit purchas
enhanc develop acceler pheno system
government initi incent hospit adopt
think pros/con ast phenotyp
talk studi process demonstr valu
proposit acceler pheno system econom well clinic
updat us progress made respiratori panel
signific opportun talk evolv
fda still expect success launch
commerci org structur team focus capit sale
specif anoth focus drive util
talk current prioriti beyond respiratori panel
plan underway expand portfolio beyond respiratori
oper model cash flow
think gross margin ramp next sever year
much growth expect see spend next
oper margin target scale
expect becom cash-flow posit
healthi eplex placement progress menu
expans off-set lighter flu season
saw meaning growth eplex placement close year
estim eplex placement despit recent slowdown util
rate due lighter-than-expect flu season also hit import
regulatori mileston complet fda submiss three bcid panel
recent submit gram-neg fungal pathogen panel fda
anticip approval/launch late year earli next year consist
previou commentari addit manag note palmetto
cg lcd final determin reimburs larger multiplex panel
larg expect follow draft guidanc would present
headwind similar lcd adopt major
gnmk respiratori test volum driven inpati test overal continu
think eplex remain differenti platform esensor technolog base
easy-to-manufactur therefor inexpens scalabl electron
compon enabl enjoy highly-attract margin
structur longer term put togeth mark strong year
solid instal number despit lighter flu season horizon stabl np
configur drive penetr distribut test locat continu
menu expans bcid littl chang invest debat
well valuat remain attract sale remain overweight
lighter flu season factor outlook lighter-than-typ flu
season confirm recent slowdown util run rate annuiti
vs expect modestli
neg reaction appear light flu season weaker
demand although data point upcom quarter help
clarifi full impact look ahead maintain revenu
guidanc kept annuiti near high-end
narrow eplex net new placement rang previous
gross margin expect remain flat due anticip mix
shift higher eplex product sale rel therebi bring full-year
gm guidanc slightli rang vs previous
said compani plan continu optim manufactur process order
make progress eplex gross margin line gross
margin eventu reach gross margin target next year
near-term continu make progress manufactur
capac extens plan support flu season on-going menu
expans final manag also note continu expans
sale organ also improv sale execut outsid
menu expans help drive consum revenu manag
continu believ annuiti per system remain feasibl
upsid driven continu menu expans outsid exist respiratori
panel compani made good progress submit complet
famili eplex blood cultur id fda recent submit gram-
neg fungal pathogen panel anticip approval/launch late
year earli next year alreadi sever system place lab
strateg earli access program ahead launch shift focu
intern resourc toward addit menu expans includ gi
panel market opportun global among novel panel
previous discuss gi panel alreadi design offer
report target competit panel current compani final
develop optim panel evalu variou panel
configur option provid maximum util offici launch
associ launch timelin yet announc
enabl fast accur multiplex test broadli applic high-
platform broaden address market fourfold lab
 alon bcid panel potenti becom
system also expect continu increas broaden test menu
along increas placement lead rapid revenu growth
sinc esensor technolog base easy-to-manufactur therefor
inexpens scalabl electron compon believ compani
highli attract margin structur longer term littl
chang invest debat remain overweight
question manag
growth strategi
pleas comment current view competit landscap
key advantag eplex offer
see greatest need multiplex test futur
util tick lower recent drive declin
key factor drove custom opt versu
compet platform eplex
good proxi adopt curv eplex system
mani placement increment vs cannib exist instal
could provid expect mani current
custom would like opt upgrad eplex
long sale cycl gener take vs ou
view biggest commerci risk bcid platform
particularli
split bcid three separ panel talk reason
behind advantag give competit
envis expand eplex test menu clinic area outsid
menu expans prioriti bcid panel launch
think flu season
 system launch point
margin capit structur
think overhead absorpt increment gross margin
next quarter year
step take increas gross margin eplex
think long-term potenti gross ebitda margin
expect revenu run-rat need reach profit
expect turn profit
scale cartridg manufactur pain point compani
give confid relev issu address
plan secondary/redund manufactur cartridg
current manufactur capac cartridg
cog chang bcid panel well menu expans
comment intellectu properti posit long
believ protect esensor technolog
await better entri point given strong tailorx
result
break-out year ghdx compani put string consist
beat rel conserv guidanc addit public much-
anticip tailorx studi also publish new england journal
medicin demonstr util oncotyp dx identifi women hr
node-neg earli stage breast cancer intermedi risk categori
benefit adjuv chemo vs endocrin therapi et alon
acknowledg potenti tailorx drive oncotyp penetr especi
ou start germani eventu franc medium-
term issuanc medicar lcd test help drive test
volum look greater consist result issuanc coverag
decis follow guidelin chang especi ou penetr level
oncotyp dx much lower perhap importantli opportunist
entri point ghdx trade ntm sale key construct
outlook maintain underweight rate rel rest
cadenc penetr increas europ follow
tailorx remain key controversi head one highlight
confer data tailorx studi also publish
new england journal medicin demonstr util oncotyp
dx definit identifi women hr node-neg earli stage
breast cancer breast cancer intermediate-risk
categori risk recurr score may benefit adjuv chemo
vs endocrin therapi et alon come june
controversi tailorx repres clear posit ghdx oncotyp
assay result like drive penetr pend guidelin chang
follow reimburs decis abroad manag
note past market penetr ghdx
share ou market penetr ghdx expect
eventu achiev penetr rate half us breast test
volum growth attribut tailorx result
expect particularli impact europ due lower penetr
start uk request eag review studi data
ahead updat guidelin follow coverag germani
iqwig complet evalu tailorx data made favor
recommend coverag expect near term franc expect
follow later agre data spur posit
guidelin chang coverag particularli ou timelin around
chang remain uncertain stock ytd vs xlv
delay around implement chang uncertainti around
volum growth look like impact lap june could present
downsid risk investor current model breast growth
y/i ou breast growth y/i note given
inher uncertainti around timelin ghdx like issu conserv
guidanc start year
oncotyp dx prostat continu make steadi payor progress small
rel breast prostat volum growth remain robust year
ytd follow final lcd favor intermedi prostat
cancer test octob cover ghdx prostat volum
coverag addit privat payor total live cover
manag continu optimist prostat given
market penetr first full year coverag
low low-risk total test volum favor
intermediate-risk patient regard privat payor usual follow
month case breast expans nccn
guidelin help
medicar reimburs win also help drive prostat
revenu develop collabor epic scienc ghdx
obtain final lcd medicar nucleu detect test late
octob later prior expect background high-psa
reflex test help determin patient metastat castrat resist
prostat cancer mcrpc may benefit continu androgen receptor
signal inhibitor arsi therapi well resist may
benefit chemotherapi ghdx estim men
advanc prostat cancer medicar coverag could benefit
know statu prior treatment model
revenu grow base medicar
recent expand biocarti collabor help drive ou growth
ghdx engag collabor sinc biocarti
develop ivd version oncotyp dx breast cancer test pcr-base
idylla platform placement date mainli europ sinc
ivd solut perform partner lab hospit expect
broaden patient reach ghdx particularli germani franc
eventu emerg market product expect launch start
franc germani recent ghdx also announc expans
collabor includ urolog develop ivd version
oncotyp dx prostat test run biocarti idylla platform similar
breast assay ghdx make royalti payment biocarti base net sale
test commerci
remain underweight given valuat acknowledg strong
tailorx readout lcd solid perform vs
expect look greater consist result issuanc coverag
decis follow guidelin chang ou perhap importantli
opportunist entri point ghdx trade ntm sale key
construct outlook maintain underweight rate rel
rest coverag
question ghdx manag
core breast cancer market penetr estim oncotyp
dx node posit node neg breast cancer
tailorx result help drive higher time-frame
exist sale forc suffici penetr remaind market
expect increment invest
think pace next step intern ramp
light tailorx data
talk stand intern reimburs
next key near-term mileston germani franc
penetr dci popul ultim get
drive
level reimburs obtain countri
outsid level reimburs
think intern sale forc requir product
sale peopl countri term per-person revenu compar
 commerci organ
evalu prostat market opportun view success
discuss prostat ramp test volum basi
compar intern expect
think competit environ prostat
market share look like expect hit profit
next mileston increas prostat reimburs
think revenu ramp
final lcd place
think current lab capac redwood citi
exist facil suffici expect intern dci prostat
beyond talk think liquid biopsi
market particularli light decis withdraw segment
give us updat biocarti collabor breast
recent prostat expect launch breast ivd
assay think associ revenu
much focu drive leverag model
major compon cost good much leverag
possibl time
think magnitud sale forc expans next
sever year area expect see increment invest
magnitud expens intern expans
much sg leverag expect next sever year
much increment expens plan particular
area focu
expect tax expens tax rate assum
think capital-expenditure need lab expans redwood citi
prioriti use cash next sever year
momentum keep us posit genet continu
go gener
rough muddi misstep guidanc quarterli volatil
made strong comeback driven new manag team set
achiev expect lever sustain core momentum amidst rapid
growth volum ytd revenu ytd look ahead
believ strateg head right direct offer
low-cost test menu scale penetr rate keep increas
comprehens test menu posit well continu take share rapidly-
grow genet test market manag note plan leverag exist
lab oper declin sequenc cost cost per sampl
reduct last year well economi scale opex particularli
within sale forc headcount expect continu margin expans next
year dynam mind maintain overweight rate
genet test market remain ripe lower cost approach
back dramat decreas cost next-gen sequenc
genet test market remain ripe rapid expans lower cost sequenc
allow test expand tradit diagnost assay broader panel
includ cancer cardio neurolog pediatr rare diseas
eventu person prevent medicin whole genom sequenc
becom afford look closer market inherit
genet condit known gene variant current genet
assay avail commerci laboratori low-cost provid
includ self-pay price panel single-gen test vs
one year ago believ posit continu captur
meaning share market institut insur contract
mix price combin volum result asp today
last year two acquisit continu reap gain expand
nvta footprint reproduct health screen market
remind acquir two small genet test compani
start genet close earli august combimatrix close novemb
start focus pre-implant carrier screen in-clin
at-hom inherit disord combimatrix clinic diagnost
lab offer test genet abnorm use miscarriag analysi
leader carrier screen preimplant genet diagnost
prenat diagnosi along diagnosi pediatr development disord
continu believ acquisit posit well expans
reproduct health screen among market drive sustain high
growth compani launch invita carrier screen june
compens deal-trigg termin start agreement
provid ec servic account start
test volum time acquisit call manag
note plan launch in-hous nipt offer
partnership kew repres nvta foray cancer diagnost
collabor kew comprehens genom profil compani
flagship cancerplex sequenc assay genom profil
tumor abil detect somat mutat cancer-associ
gene along ultim aim match patient target therapi
solid tumor collabor base develop comprehens genom
profil solut sequenc tumor dna nvta next gener
sequenc platform ad kew somat mutat detect capabl
nvta extens portfolio diagnost genet test panel
gain exposur rapidly-grow cancer diagnost cancer
treatment select field regard specif collabor
fund collabor develop effort build-out product
capabl integr kew technolog platform workflow
also gain access kew proprietari bioinformat softwar high-
perform analyt capabl believ collabor bring much
promis given emerg comprehens genom profil gold
standard care coupl high-effici low cost access
nvta platform joint commit lower cost
reimburs trend right direct continu make
progress ad addit payor payor coverag reach
critic mass compani expect revenu ramp continu outpac
volum growth recent new studi publish journal clinic oncolog
support univers genet test breast cancer patient research
tme breast network network lead breast cancer
physician along found current guidelin genet test
breast cancer patient miss mani patient genet mutat pathogen
variant find support broaden current guidelin
progress studi support broader clinic adopt promot
advanc reimburs front time earlier year
compani issu long-term target perform test translat
revenu gross profit exceed oper expens
time final began receiv payment medicar delet
duplic analysi code moreov compani expect
paid medicar del/dup colon cancer improv collect
rate third-parti payer well
maintain overweight step back encourag solid year
reimburs volum front latter remain
import indic busi continu believ
strateg head right direct offer low-cost test menu
scale comprehens test menu posit well take share
rapidly-grow genet test market continu see addit upsid
attract setup given conservat embed guidanc
despit increas continu momentum busi
drive leverag time importantli focu meaning rein
question manag
overal growth strategi
cost come landscap seem get competit
new compani enter market consolid etc view
nvta competit differenti allow take share
view potent competitor today think
competit landscap long-term incumb
refer clia lab academ medic center
think gain mindshar doctor word
convert doctor werent use genet test past use
year sinc acquir goodstart combimatrix
help enter new account cross sell better surpris
upside/downsid two deal
given youv launch invita carrier screen june compens
deal-trigg termin start agreement provid
ec servic see traction new test challeng
deal develop ec servic
plan grow arm busi go forward
counsyl part well rapidli gain share
potent competitor ec panel see addit
competit pressur plan respond
youv discuss plan launch in-hous nipt offer
provid color test differ nipt offer
price expect sell associ cost per test
impact expect top-line
previous youv indic tent bundl test includ nipt
low price someth still contempl would
talk current tier price structur rational
put new structur place impact see
talk rational go up-front price
point base competitor activ intern cost market
studi would drive market expans someth els
turn reimburs progress alway uneven seem gener
trend right direct give us color stand
expect pictur evolv next coupl year
work payor pitch valu proposit
bring tabl talk sell better qualiti test lower
price also lower overal cost care patient health
econom data indic point see publish
data along line road
common pushback payor reimburs today given
payor friendli stori simpli need see data
much lower think go term sequenc cost
think time
expand product offer beyond cancer genet
disord includ cardiolog neurolog pediatr etc outsid cancer
view next big opportun genet test earli
traction like panel
talk long-term plan develop genom manag busi
progress made date front
light collabor kew expect timelin
commerci somat test differenti offer rel
entrench incumb like fmi academ center etc
mileston
liquid biopsi remain hot topic view major opportun
space
comment interest pharma term partnership
view fda grow involv space regul
ldt
oper model cash flow
obvious cost leadership continu key focu point especi
lower price point talk area
view biggest opportun push addit cost particularli around
lab autom lever pull term reduc cost
intern distribut strategi key market
emphas need improv collect describ
area focus improv progress date
key hurdl need address hit gross margin
remind us term sale forc size
pace increas headcount
hit scale expect sg cost end
revenu time-frame gross profit exceed opex longer
term expect oper margin look like
expect capital-expenditure spend pace next year
long-term secular challeng busi
uncertain reimburs outlook genesight leav us
myriad genet remain one highly-deb name coverag
univers bear focus long-term secular headwind core
hereditari cancer segment headlin continu y/i price pressur
compet test still price well myrisk bull point near-term q/q
price stabil hc revenu three-year contract albeit
volum commit multipl call option embed pipelin
headlin genesight step back histori beat
low bar long-term question around stabil hereditari cancer
busi contract renew term hh subpoena impact limit evid
privat payor reimburs physician accept genesight failur
meet primari endpoint off-set statist signific remission/respons data
health econom assess still pend uncertainti follow recent
fda letter pharmacogenom test remain address
hereditari cancer continu post meaning declin price
headwind although volum trend improv increment upsid
cdx segment continu post consist ldd declin lsd
volum growth off-set dd y/i price declin relat long-
term contract even q/q price remain stabl look ahead volum
remain steadi increment upsid cdx met bc launch
fda approv bracanalysi cdx first-lin mainten ovarian
cancer japanes hboc/cdx test long-term price pressur remain
practic rais question around compani abil continu bill
expens instead code uncertainti
whether final rule crosswalk new brca code
broader commerci reimburs genesight remain uncertain
genesight volum continu ramp new coverag carefirst
larg employ broader commerci coverag remain uncertain due
multipl headwind includ delay expect genesight studi
public led reduct expect revenu
recent fda statement pharmacogenom test say test report must
support intend use consist fda-approv use
medic view genesight may satisfi requir
make recommend outsid label fda-approv
medicin word genesight tell drug work
label drug genesight predict anyth
contrast say brca companion dx put anoth way intend use
prozac use base genesight test result
recent fda statement relationship dna variat
effect antidepress medic never establish
made genesight data present spring although
data impact studi current review
counsyl acquisit add exposur high-growth albeit highly-
competit prenat test market signific revenu synergi
opportun embed current guidanc earlier calendar
year acquir counsyl gain exposur high-growth albeit
competit expand carrier screen ec non-invas prenat test
nipt market howev despit low degre overlap
counsyl custom signific cross-sel opportun manag
surprisingli assum revenu synergi first year busi
experienc reimburs headwind due out-of-
network statu sever catalyst place drive upsid manag
conserv expect includ anticip acog guidelin expans
average-risk nipt improv reimburs ec return in-network statu
revenu synergi cross-sel
final broader perspect continu cautiou view
ldt busi model past esoter ldt market
view sit nexu secular shift healthcar toward
person medicin vision view run realiti
ldt busi model number challeng mani lab attempt
support pharma model center around heavi rep count
signific up-front cost without benefit patent protect moreov
well document get paid continu signific hurdl
payer particularli privat side still reluct establish coverag
even highly-util test view dynam surpris given
part continu lack fda oversight question around test
efficaci econom valu although slowli improv furthermor
reimburs establish lab still neg impact
subsequ non-coverag decis action taken payer limit test
util matur market like hereditari cancer face signific
pressur lower cost competitor color refer lab etc
mind surpris see lead ldt compani space
includ pivot pharma partnership supplement clinic
busi industri wait reimburs gordian knot
maintain underweight put togeth histori
beat low bar long-term question around stabil hereditari
cancer busi contract renew term hh subpoena impact
limit evid privat payor reimburs physician accept
genesight failur meet primari endpoint off-set statist signific
remission/respons data health econom assess still pend
uncertainti follow recent fda letter pharmacogenom test remain
address remain underweight
question manag
youv previous mention your penetr hereditari cancer
market take increas penetr
what strategi expand test volum patient low famili
histori extent recent launch riskscor indic
expans help increas penetr think
sustain level test volum growth medium long term
talk trend see competit landscap
market segment see competit pressur
see meaning competitor prevent care segment given
one sale reach view lower cost provid
competit threat direct-to-consum genet test compani
discuss cms/oig around bill practic hct
sinc receiv hh subpoena februari give confid
continu abl bill expens instead
relat new sequencing-onli brca code give
confid final rule crosswalk
hereditari cancer revenu cover contract
remind us exactli contract work minimum volum
commit incent payor enter contract price
seem posit keep fall major payor contract renew
risk around lower
much payor abl drive test physician use obviou thesi
payor push doctor use lower-cost test alway
case practic
much market share expect abl retain brca market
next year three year
increment commerci invest requir expand non-
breast cancer indic expect opportun ramp
expect signific guidelin decis non-brca test near futur
talk cdx opportun size bracanalysi mychoic
hrd expect begin meaning impact
volum cdx opportun explor what view
competit landscap cdx
light recent fda statement pharmacogenom dtc test
risk might pull genesight market given
fda explicitli told manufactur test report must support intend
use consist fda-approv use medic
genesight satisfi requir clearli make recommend
outsid label fda-approv medicin
give us updat payor convers genesight
fda letter impact discuss given
statement relationship dna variat effect
antidepress medic never establish etc expect
addit privat payor coverag decis genesight
could see lcd expand coverag primari care physician
genesight volum grow ahead expect
primari driver
talk competit landscap mental health test
current dedic salesforc genesight much
increment salesforc invest need secur reimburs
walk us strateg rational counsyl deal plan
leverag expand carrier screen ec nipt offer
counsyl leader ec market share competit other
includ increas plan differenti offer
nipt view larg commodit offer acog wide
expect publish support view nipt women
view payor half still hold may necessarili follow
coverag decis averag risk pregnanc right away
view reimburs progress averag risk set
forecast assum flat growth counsyl revenu
synergi despit clear opportun cross-sel best-in-class
combin sale forc cost front walk us
lab gc autom techniqu could potenti roll
larg vectra opportun go take drive
penetr market given one matur product
expect announc major vectra privat payor win
type growth profil expect prolari next sever
year volum revenu drive volum growth increas
store sale increas number urologist order test
next mileston watch prolari commerci
talk key point differenti prolari
compet test ghdx outsid ghdx prostat test
view viabl competit threat prolari
give updat competit environ endopredict what
current commerci strategi seen chang commerci
strategi entrench competitor oncotyp dx much market share
abl captur
type revenu ramp expect see endopredict
next year would consid win
talk mypath melanoma opportun could
potenti see nccn guidelin updat reimburs win
view sustain long-term oper margin busi
model public competitor target opm scale
essenti look drive volum feasibl model
expect gross margin oper margin trend
integr counsyl assurex busi progress
updat thought cost synergi opportun longer term
primari area cost save date
talk commerci invest make next
month particularli area outsid hereditari cancer
what current capit deploy strategi priorit pay
debt vs repurchas share vs
term current area focu look addit
deal interest opportun pipelin
robust broad-bas growth across portfolio includ
pick-up consum pull-through focu
remain dsp launch
strong year nanostr compani saw progress
multipl front product servic sale consist come
estim driven strength consum pull-through grow instal
base unit y/i facilit sale channel invest last
year bifurc sale forc coupl steadi growth instrument
revenu y/i led robust demand biopharma custom
drove instrument revenu direct market servic
side strong traction geomx digit spatial profil technolog access
program drove sustain revenu ramp new project order
project order date see dsp kol debrief color
collabor revenu also remain robust albeit rel light due
pace hyb seq spend deriv partnership
overal come year encourag sign stabil last
quarter given long-term growth potenti consum driven
expand instal base well adopt prosigna test
underli valu technolog pipelin hyb seq geomx dsp
latter track launch maintain overweight rate
broad-bas growth complement avenu sustain momentum
continu see robust growth prosigna y/i
benefit posit health technolog assess includ uk
draft guidanc ad prosigna final set
stage prosigna becom widely-avail uk patient start
moreov instal base increas last
twelv month sprint account instrument placement
expect continu placement core ncounter system lay
foundat sustain upward trajectori consum prosigna
y/i combin oncolog remain primari growth engin
busi account new instrument placement direct market
pancanc panel grow y/i also made
signific progress increas awar ncounter outsid oncolog
instrument sale deriv area outsid oncolog
particularli immunolog neurolog meaning contribut
pipelin remain track strong earli interest dsp ahead
launch turn pipelin progress remain track particularli
strong earli custom interest geomx dsp platform still
expect launch remind launch
access program year ago custom complet
project process sampl date posit result note
least ten abstract present major scientif meet public
compani follow earli access launch august
addit three center excel select five site one cro one
pharma compani three academ center receiv beta instrument
begin light robust custom interest earli access demand
clearli exceed five site note earlier within month announc
also announc launch geomx prioriti program
particip among first receiv geomx instrument
limit first particip purchas commerci system
follow expect commerci launch light robust custom
interest feedback around price point featur set plex throughput
compet technolog manag confid abl support
price instrument via capit sale believ
market reagent rental within research segment furthermor
encourag grow clinic valid among sever studi
technolog alreadi dsp program recent yield two independ peer
review paper natur medicin one co-author jim
allison md anderson recent nobel prize immuno-
oncolog work manag mention call expect dsp
launch evolv similar manner sprint launch note expect
sell dsp system recogn revenu full unit
meaning progress hyb seq menu expans initi
term hyb seq remain ruo continu make progress
sever potenti applic includ genotyp ast given speed
abil platform simultan sequenc dna rna
latter show potenti see recap color next major
updat hyb seq unveil agbt confer final
along call announc launch new gene express
panel ncounter car-t character panel molecular
character car-t cell creat collabor eight lead
center use across entireti car-t workflow includ
manufactur post-infus monitor car-t panel expect
begin ship though expect materi contribut right
outset although hyb seq ncounter car-t panel remain long-term
growth opportun believ manag make good progress
expect contribut ramp time
remain overweight step back encourag continu sign
stabil consist top-line beat continu dsp traction
manag new approach forecast outlook confid meet
sometim exceed continu bode well compani opinion
given long-term growth potenti consum driven expand
instal base well adopt prosigna test underli
valu pipelin geomx dsp hyb seq remain overweight
question manag
product market
highlight improv commerci execut due recent chang
sale forc addit consum focus rep one driver
strength addit impact expect bifurc sale
forc go forward anyth els remain done term
optim commerci channel
share updat view academ market head
given biopharma custom drove instrument revenu direct
market share updat view expect demand
biopharma custom head
youv mention oncolog remain primari growth engin
busi someth forese go forward driver suggest
sustain growth point
given goal also increas awar ncounter outsid oncolog
instrument sale deriv area outsid oncolog
particularli immunolog neurolog expect mix look
like area target along immunolog
neurolog
penetr rate ex-u market ncounter
given uk draft guidanc includ prosigna
final see first step prosigna becom wide
avail uk patient start much progress expect
give addit color prosigna ramp expect adopt
acceler
compar contrast pace prosigna adopt seen
 ou market key factor
note prosigna demonstr grow capabl
diagnost commerci leverag across entir menu
test time test expect commerci near
medium term near-term mileston watch
mention expect car-t panel begin ship
much contribut expect right outset rate
forese ramp remind us market opportun car-t
give us updat dsp platform still track
commerci assum term dsp
guidanc post-launch still expect sell dsp system
recogn revenu full unit like saw posigna
help us dimens size potenti opportun etc
platform
term dsp technolog access program increment servic
revenu expect
comment develop statu hyb seq platform
follow lam collabor design offer library-fre
amplification-fre singl molecul sequenc pace
hyb seq lam collabor revenu target market
program compar target panel instrument
competit expect see next mileston
margin capit deploy
current cash burn think
think long-term potenti gross ebitda margin
near-term lever pull increas gross margin
think sg growth attempt reacceler product
revenu prepar commerci launch digit spatial profil
think spend percent revenu light
effort commerci digit spatial profil hyb seq
help us think long-term model level revenu
estim compani becom profit
strong nipt/ec franchis still earli day
disappoint close compani grappl
delay turnaround time ensu revenu pushout limit progress
average-risk nipt reimburs front still news acog guidelin
revis support nipt use pregnanc despit expect would
issu along earn compani also lower
midpoint revenu guidanc manag attribut longer-than-
anticip delay revenu recognit cord blood oncolog test
translat temper revenu growth outlook posit side plan
remain place launch clia version signatera ctdna assay cancer
recurr monitor solid traction ruo set
pharma partnership date follow kidney transplant reject test
recent receiv uniqu z-code encourag pre-submiss meet
look ahead continu believ leverag
market-lead posit nipt/ec coupl ramp contribut
pipelin drive robust albeit temper top-line growth medium-term
given underwhelm close year delay acog bulletin littl
differenti compet nipt/ec test escal competit
reproduct health test market could effect intensifi guidelin
support acog price like erod steadili time continu
see limit upsid current level pend greater visibl pipelin ramp
pleas see recent initi color thesi
expand average-risk reimburs remain key catalyst nipt
segment current nipt market primarili focus high-
risk pregnanc per year penetr opportun lie
under-penetr average-risk market test per year
penetr remain rel untap due limit reimburs
specif live current cover average-risk
pregnanc larg payor like aetna still
hold expand average-risk reimburs remain key catalyst
acog larg expect issu revis guidelin support nipt
use pregnanc october/novemb follow withdraw
committe opinion earlier year state nipt
appropri first-lin screen tool gener popul still
news guidelin revis hamstr progress
reimburs front privat payor less like expand reimburs
coverag without revis guidelin furthermor guidelin revis
issu payor may immedi follow suit often polici revisit
fix time interv annual basi decis sometim arbitrari
scope appeal delay timelin expand
reimburs moreov microdelet test also offer
add-on panorama five syndrom rare cover unlik
cover near-term pend evid util
hope jumpstart smart studi plan releas data
success enrol women year
intensifi competit nipt segment hamstr price
 market leader test volum high-risk
average-risk panorama assay henc like benefit
expand average-risk reimburs nipt test limit
differenti among peer price like erod steadili time
competitor contempl bundl reproduct health offer
other sequenom counsyl part much larger
diagnost lab establish sale channel escal competit
reproduct health test market could effect intensifi
guidelin support acog price like declin time
continu see limit long-term upsid broader nipt market said
believ expand nipt reimburs averag risk pregnanc
remain matter rather privat payor traction like
follow acog guidelin revis therebi provid short-term upsid
potenti nipt market
ec penetr continu increas steadili time ec becom
wide avail partli driven support guidelin reimburs
includ recent preliminari cross-walk price
carrier screen panel gene limit addit cost associ
ad condit panel perhap importantli grow
appreci fact genet disord individu rare
individu carrier least one despit broad avail
ec clinic traction limit date pregnanc
expect market expand awar grow term competit
dynam counsyl domin market share
though increasingli competit sever compani
enter space includ launch invita carrier screen
test earlier year
pipelin hold intrigu long-term potenti also reiter
plan launch clia version signatera ctdna assay cancer
recurr monitor follow solid traction ruo set
pharma partnership includ bristol-my squibb merck
recent manag expect contract busi
meanwhil data signatera continu show earli promis
breast cancer i-spi studi univers leicest imperi colleg
joint studi recent unveil san antonio breast cancer symposium
show cohort high-risk early-stag breast cancer
patient chang measur ctdna accur predict therapeut
respons well tumor burden determin imag cohort
breast cancer patient receiv adjuv therapi molecular
residu diseas detect lead time two year prior clinic
radiolog detect median month rang month
initi result encourag look large-scal evid
clinic util signatera particular respect uniqu approach
track frequent clonal mutat patient tumor
accur predict risk relaps across multipl cancer type stage
final also plan launch kidney transplant reject test
recent receiv uniqu z-code encourag pre-submiss
meet also look forward initi result studi
examin clinic valid accuraci test includ random
studi patient run jointli qure healthcar expect
complet
maintain neutral step back continu believ
leverag market-lead posit nipt/ec coupl ramp
contribut pipelin drive robust top-line growth medium
term given temper top-line growth rate delay acog bulletin
escal competit reproduct health test market continu
see limit upsid current level pend greater visibl pipelin
ramp factor mind maintain neutral rate
question manag
specif talk delay turnaround time saw
attribut step take avoid issu go
given decreas midpoint revenu outlook along
call due longer-than-anticip delay revenu recognit cord
blood oncolog test share color issu aros
step take reduc impact expect pictur
evolv
believ reason expect acog guidelin revis
share color expect term content
pace expect privat payor traction proceed post tent
acog guidelin revis averag risk nipt particular know
larg payor aetna still hold sort
step take help facilit expand reimburs
expect price declin panorama horizon among test
pace
believ driver sustain volum growth panorama
horizon within nipt ec market respect
current penetr estim high risk averag risk
nipt market well ec market
much market share estim current panorama
horizon test nipt ec market respect
envis competit landscap evolv time particularli
consid robust competit counsyl sequenom
mention contempl bundl reproduct health
offer would impli offer nipt almost free would
respond happen
success enrol women updat
progress smart studi microdelet test
expect see result expect respons data
especi reimburs front
progress date scale busi intern market
pace expect abl grow arm busi
term ten-year collabor relationship
help drive intern penetr far much
yet recogn rate expect receiv remain
give us addit color traction see
constel cloud-bas analyt platform help increas penetr
initi expect consid ad new function
updat softwar go forward
pleas remind us framework behind uniqu take liquid biopsi test
use signatera ctdna assay studi point
track frequent clonal mutat patient tumor
shown accur predict risk relaps across multipl cancer type
still expect launch signatera clia test mileston
hope accomplish
youv mention breast stage colon stage lung cancer
low hang fruit signatera clia test post launch still
take progress expect traction
given solid traction ruo set pharma partnership
expect achiev contract busi see
achiev signatera ruo contribut mileston
still anticip sign larger deal pharma time phase trial
expect gener phase trial pace
expect sign larger studi
updat partnership bristol-my squibb phase
prospect lung cancer trial use signatera partnership
sign merck phase trial around
still expect launch kidney transplant reject test
mileston hope achiev
given recent receiv uniqu z-code kidney transplant reject
assay encourag pre-submiss meet provid
updat expect draft lcd releas
expect receiv full approv moreov youv mention plan negoti
price directli moldx cross-walk price place
caredx allosur like current see outcom
talk view competit kidney transplant
reject test post launch particularli consid compet
allosur date ad center
transplant screen procedur repres transplant volum
 step plan take win custom given
current plan expand use case kidney transplant
reject test includ organ transplant
call mention new dna techniqu reduc cog
go forward benefit per test get
object overal product cog per test impact
cog step plan take
reach cog goal
think opex particularli continu develop
pipelin
tb continu drive growth deal
pave path acceler
oxford immunotec oxfd event culmin deal sell
 lab servic busi cover analyst
lisa gill cash come decent valuat sale
repres right strateg move view step back encourag
see continu healthi growth tb believ momentum acceler
deal well recent product innov around autom
drive market penetr bottom line deal also
significantli improv profit addit potenti upsid go forward
capit deploy factor mind along attract
valuat sale remain overweight
adjust recently-divest servic busi oxfd report
revenu cc includ divest busi revenu would
slightli street importantli tb
revenu includ divest busi continu see healthi
momentum cc asia cc eu/row
consid complic associ intra-quart deal close although
tb revenu expect declin q/q due weather-rel disrupt
japan compani expect provid clariti top bottom line
outlook provid guidanc next quarter step back
continu believ t-spot tb test oxfd well posit
latent tb test market remain penetr igra
global two avail test t-spot tb qiagen quantiferon
histor t-spot tb advantag quantiferon includ
workflow sensit although comparison newly-
launch quantiferon-tb gold yet seen said market
larg enough one supplier furthermor contrast mani
earli stage compani oxfd clear fda reimburs hurdl t-
tb approv countri includ recent china
news t-cell select kit receiv regulatori accept
china food drug administr cfda test also
reimburs uniqu code
equival code quantiferon
deal bring sever strateg merit focu product revenu
significantli improv profit servic revenu
kit revenu test volum would
net divest revenu impli sale transact multipl
decent given servic gross margin upon deal close oxfd sell tb
test kit seven-year suppli agreement price similar
current ou kit henc maintain product margin deal expect
close subject customari regulatori approv close condit
compani expect provid pro forma financi deal close
abil leverag dgx commerci reach acceler growth
manag provid detail test volum expect deal
dgx broad lab network enabl oxfd better penetr larg
physician offic market therebi acceler volum growth beyond
acquisit compani also enter collabor grow t-spot
tb test effort sale market medic educ
due larg profit gap product gm servic
gm divestitur servic busi transform oxfd pure-
play kit compani significantly-enhanc gross margin profil
support valuat re-rat ev/sal basi henc stock move
today bottom-lin impact depend much sg
carv oxfd still final personnel chang expect
signific manag provid financi color post deal close
furthermor see potenti signific gross margin expans
compani continu drive intern cost process test
deal proce increas capit deploy flexibl
cash proce deal significantli strengthen oxfd balanc sheet
part proce use pay term loan
remaind afford compani plenti capit deploy option
 dividends/buyback term use proce
debt paydown compani also explor capit deploy
option includ dividends/buyback although latter
manag note process complic due regul expect
provid clariti plan proce along explor
process compani expect use proce fund meaning
increas expens
reiter overweight latent tuberculosi test market estim
remain extrem under-penetrated penetr igra
global expect number significantli increas next sever
year confid core latent tb test growth well
compani abil leverag dgx commerci reach acceler market
penetr move right side diagnost lab market consolid
oxfd previous lost small hospit lab custom consolid like
greater focu kit technolog well significantli
improv profit financi flexibl remain overweight
question oxfd manag
walk us reason deal decid
sell lab servic impact expect
given increas capit deploy flexibl come deal
expect use proce term continu
look acquir market key metric technolog
look potenti acquisit
level revenu need becom profit
expect time profit
adopt market penetr igra test slow given
quantiferon market year
elabor advantag particularli workflow test
quantiferon quantiferon-tb gold
convert custom quantiferon immedi
gain volum transit work
much increment competit pressur seen launch
one primari reason heard adopt igra price
test discuss think igra cost benefit compar
tst long term
discuss ou opportun particularli market size europ
china japan
discuss countri regulatori approv
reimburs
term futur applic market see attract
larg
meaning progress organ acceler margin
expans high hurdl leav littl room
mistak
deliv solid ytd perform cer
organ top-lin growth driven continu strong mdx momentum cer
significantli improv prospect achiev compani goal
organ compound-annual-growth-rate albeit origin goal laid
organ growth includ qiastat acquir howev given
lack luster organ growth hurdl high
believ buysid expect organ growth leav littl room
mistak view qiastat main sourc risk light
competit landscap reimburs environ along fda assay
approv time risk bottom-lin qiastat dilut fx headwind
could cap near-term ep growth least long-term expect
cannib qiasymphoni neumodx also worth watch
factor mind remain neutral believ posit larg reflect
current valuat ntm price-to-earnings view evid qiastat traction
quarter continu improv life scienc portfolio
current lag peer key construct view
mdx portfolio continu advanc multipl front start
quantiferon qft momentum remain strong cer despit
difficult comp south korea tender cer last year launch
gener qft allow franchis continu strengthen
domin market posit manag continu expect tb
revenu improv product autom diasorin partnership
access liaison instal base recent guidelin expans
sustain acceler strong test volum growth dgx recent
acquisit oxfd expect minim impact given dgx
on-going commit qft annual sale qiasymphoni growth
remain robust dd instrument placement cumul
placement ye last year consum turn
portfolio sale year generead current system
place achiev dd share benchtop oncolog market
along europ previou traction cap limit
initi menu recent launch new oncolog panel well increas user
valid show concord ilmn miseq workflow advantag
particularli around bioinformat acceler adopt go forward
univers solut portfolio also see continu growth
broader market addit potenti recent launch rna
sequenc solut final revenu cdx co-develop amount
ytd cer continu grow new cdx approv
five expect year
life scienc portfolio benefit healthi end market
room improv compar peer ytd pharma grew cer
meaning slowdown cer growth last year contrast continu
hsd end market growth academia remain healthi cer led apac
region improv fund environ across globe appli
test declin due headwind divestitur veterinari
test busi well difficult comp cer last year forens
order remain lumpi overal manag continu recogn room
improv life scienc perform upgrad product portfolio
current consist mostli sampl assay technolog lack
killer instrument platform year compani also look
activ organ inorgan potenti ad new instrument
help stimul lock consum sale
focu organ acceler achiev long-term target
organ compound-annual-growth-rate compani yet provid
offici guidanc manag current expect organ growth
next year believ buy-sid expect closer need
make lack-lust organ growth order achiev
compani goal organ compound-annual-growth-rate mdx
remain growth pillar continu momentum quantiferon
qiasymphoni similar acceler portfolio
increment revenu expect organ contribut next year
 launch qiastat increment revenu
expect organ contribut light high expect think key risk
number could come qiastat includ uncertainti around assay
approv time stricter reimburs syndrom test outpati
set although qiastat flexibl tailor panel reimburs
environ competit strong incumb system especi
biomerieux/biofir grew ytd turn life scienc pharma
academia remain healthi robust activ improv
global fund environ potenti addit new instrument
platform next year provid upsid appli test also
benefit easier comp divestitur headwind lap
pend neumodx acquisit complement mdx portfolio
announc strateg partnership neumodx market
autom pcr platform ou acquisit compani
conting success menu expans target latest
differenti neumodx platform includ fast turnaround minut vs
hour competitor system posit system well first-lin
rapid diagnost true random access allow lab consolid ldt
mainstream assay onto platform small footprint integr
pcr market annual replac opportun system
qgen market reach greatli benefit broad exist modul
pcr qiasymphoni custom base although convers incumb
system panther roch coba like gate long-term
reagent contract commerci test manag goal deal
ep neutral year one accret soon howev move
modul integr pcr clear trend faster turnaround less labor
demand neumodx expect gradual cannib qiasymphoni rgq
next five year menu expand
margin expans continu although near-term ep growth
limit qiastat dilut fx headwind also show good
progress opm expans bp ytd help qft gross margin
improv due in-sourc manufactur product mix cdx accret
ebit margin sg leverag share servic site complet
earlier year servic reloc on-going expect margin
expans trajectori continu manag target bp annual
improv medium term said near-term margin expans
limit qiastat dilut least launch
potenti neutral full-year impact fx headwind
maintain neutral overal encourag signific organ
acceler year high hurdl leav littl room mistak
qiastat main sourc risk bottom-lin qiastat
dilut fx headwind also like cap near-term ep growth least
long-term expect cannib qiasymphoni
neumodx also worth watch mind believ
posit larg reflect current valuat ntm price-to-earnings view
evid qiastat traction quarter continu
improv life scienc portfolio key construct view
question manag
give us overview portfolio transform compani
gone recent year chang organ growth profil
compani see portfolio evolv go forward
biggest develop envis
midterm target organ compound-annual-growth-rate impli
signific acceler next year given msd organ growth
talk key driver fuel acceler
put take lead low end vs
high end rang
speak briefli underli growth rate end market
competit posit within academia pharma appli
molecular diagnost strengthen competit
biggest sourc adopt underpin target tb
revenu light sever recent guidelin updat tb test
us immigr think potenti updat target
anticip country-level tb test guidelin expans
horizon current govern tender pipelin look like
regard partnership diasorin give us updat
traction far revenu potenti mani diasorin
instal base think ultim penetr what econom
partnership chang price margin per test
give confid see similar price pressur
seen hpv give histor analog think
context market segment grown consist
competitor price pressur mayb sequenc
qiasymphoni placement continu strong main
driver main expans opportun qiasymphoni
give us overview current menu offer qiasymphoni
recent progress made term menu expans
see opportun util pull-through evolv
much upsid
see chang competit dynam market abbott
process releas new famili system beckman tri
reacceler market growth rate roch continu perform well
key point differenti qiasymphoni compet
percentag qiasymphoni placement rgq see
meaning differenti region choos util system
opportun drive fuller util across instal base
view potenti cannib qiasymphoni rgq
differenti qiastat-dx compet system biofir eplex
aries/verigen much share think captur
talk launch plan target custom plan target
custom new molecular test competit take-out
well posit think qiastat light stricter reimburs
syndrom test outpati set
place generead far market forens
oncolog placement expect placement ramp next year
broader oncolog menu
remind us averag consum pull-through per system
expect increas time
light recent announc partnership around nipt
discuss thought competit landscap nipt
think generead edg specif market target
larg qgen bioinformat busi current growth
rate expect meaning acceler
proport cdx partnership proprietari
biomark econom outlook proprietari biomark
see greatest opportun futur growth cdx
view key competit advantag lead pharmaceut
compani elect partner versu competitor
think busi adapt presenc
sequenc risk cannib current pcr busi
appli busi continu show strong growth talk
drove long-term growth rate market
talk current academ demand environ region
much increas nih budget could boost end market growth
pharma growth past quarter meaning acceler
previou msd level besid healthi end market fundament
dynam contribut growth
margin cash flow
midterm outlook call ep compound-annual-growth-rate cer
key lever drive beyond expect top-lin growth
see opportun expans gross margin
what target opm level key lever pull achiev
optim level expens longer term
discuss restructur activ your pursu mitig impact
tax reform
your target oper cash flow signific
increas current level get specif opportun
identifi far
discuss latest think around capit deploy prioriti
acquisit compani give us updat deal
pipelin area focus drive inorgan growth
metric use evalu potenti deal
seen mainli bolt-on past coupl year could see
larger strateg deal level would will take
leverag right deal
focu remain triage/bnp pipelin near-term
season headwind lighter flu season well
neg initi outcom bnp disput
in-lin year steadi top-line growth despit modest
miss due season headwind includ earlier end flu
season well light flu season horizon acquisit
triag asset aler year ago progress smoothli repres
meaning diversif revenu base away volatil flu swing longer-
term term menu expans triag troponin assay expect launch
europ toxicolog panel expect launch follow
strep assay sofia head focu remain
steadi progress triage/bnp integr along success menu
expans although lighter flu season rel last year like remain near-
term overhang lastli regard on-going bnp disput beckman
summari adjud decemb yield neg outcom rule
put end litig trial schedul august
intend submit appeal court review decis
although manag continu confid ultim prevail
litig note bnp constitut revenu ytd
account close qdel total ebitda given assay gener
ebitda posit beckman like continu
sell assay honor suppli agreement see take
current assum busi usual chang part
oper model step back result legaci busi present mix
pictur larg due season headwind neg initi outcom
bnp disput beckman add element uncertainti well downsid
potenti number remain encourag integr progress oper
improv head said continu believ aspir
organ acceler outlin april analyst day remain show-
stori look evid success commerci pipelin
opportun sustain reacceler triage/bnp well favor
conclus beckman litig key construct view
stock remain neutral
legaci busi present mix pictur recent report
revenu came slightli jpme/consensu
softer cardiac perform vs jpme partli off-set
acceler molecular vs rapid immunoassay
saw continu yet less dramat declin vs due earlier
end flu season special dx remain in-lin vs jpme
bottom-lin ep beat jpme/street aid
continu progress align manufactur support function relat
triage/bnp acquisit note like lighter flu season although
manag note still expect pocket influenza
present element uncertainti near-term headwind legaci
oper integr triage/bnp progress smoothli integr
triage/bnp busi progress well transit alreadi
complet facilit establish commerci
infrastructur transit also almost fulli complet ou
market build direct commerci capabl china
last remain geographi complet expect
compani upgrad erp system cloud-bas system outsid
manag expect incorpor middl next
year order connect integr system global
although acknowledg meaning progress made sever
front view sustain reacceler triage/bnp revenu grew
y/i declin q/q vs due weak triag
partli off-set strength bnp key particularli consid weight
overal portfolio challeng pose given stagnant perform
pre-acquisit competit environ synergi front manag
recent note compani run better origin plan
total synergi expect synergi
compani exit set object exit total
synergi manag believ achiev given
reduct head count date well on-going progress sever
initi improv yield reduc scrap integr manufactur
process lastli regard on-going bnp disput beckman summari
adjud decemb yield neg outcom rule
put end litig intend submit appeal
court review decis trial current schedul august
although manag continu confid ultim
prevail litig note bnp constitut revenu ytd
account close qdel total ebitda given assay
gener ebitda posit beckman like
continu sell assay honor suppli agreement
pipelin opportun provid long-term upsid potenti
receiv two fda approv solana molecular assay
diagnosi pertussi parapertussi complex lab easy-to-us
clia-waiv sofia lyme whole blood test term menu expans
triag troponin assay expect launch europ
toxicolog panel expect launch follow strep assay
sofia recent receiv ce mark
triagetruetm high sensit tropononin test turn part
pipelin still work assay develop savanna expect
launch system europ launch expect follow
look evid success commerci
pipelin asset fruition upsid potenti upcom quarter
near-term outlook reiter look ahead guidanc continu call
revenu although uncertainti around strength flu season
present near-term headwind quarterli run rate cardiac sale
msd long-term growth outlook gm guidanc recent
increas due continu oper improv particularli light
meaning progress align manufactur process
maintain neutral step back result legaci busi present
mix pictur larg due season headwind neg initi
outcom bnp disput beckman add element uncertainti
well downsid potenti number remain encourag integr
progress oper improv said continu believ
aspir organ acceler outlin april analyst day remain
show-m stori look evid success commerci
pipelin opportun sustain reacceler triage/bnp key
construct view stock
question manag
comment recent trend flu demand would character
season compar previou season
visibl flu demand chang time
model longer term rapid flu test market growth rate
percentag flu revenu attribut sofia
key benefit sofia offer sofia
menu develop prioriti sofia
talk sofia custom base gener mani
new custom versu exist custom updat
updat thought reimburs flu test
recept sofia sofia instrument remain strong given solid
placement perform primari attribut offer
system drive robust perform
remind us sofia sofia econom flow
sofia test clear think per-box annual pull-
chang sofia
pleas updat us commerci timelin savanna platform
 ou market
develop timelin savanna larg revenu
molecular diagnost market becom increasingli crowd
talk key attribut set savanna apart compet
updat thought initi menu expans plan
savanna
custom recept solana instrument
primari use case
think next step term solana menu expans
type gross margin expect system gener continu
scale instal base
plan achiev revenu growth acceler flat msd
triage/bnp
plan improv gross margin profil triage/bnp
triage/bnp diversifi revenu base away flu volatil
expect growth mix look like company-
level triage/bnp revenu ramp
share updat on-going bnp disput beckman
timelin make confid ultim prevail
would recent decis affect busi near-term
think sustain non-flu season gross margin
pleas remind us long-term target new product
launch addit dilut goal
current manufactur capac util room
ration excess capac particularli legaci product line
give us updat thought need grow sale headcount
launch new product particularli molecular space mani head
need add properli support commerci roll out
room reduc sg spend much leverag expect
line
think spend associ variou
develop program balanc increment invest vs
ebitda margin target key lever get
goal
expect tax rate go forward tax strategi
action execut reduc
recent done good job use excess cash pay debt
associ aler transact your leverag
use excess cash contempl think
go-forward basi capit alloc
gap portfolio see potenti tri fill
solid start fiscal year continu volatil
calendar mix bag headlin signific quarter-to-
quarter volatil posit side demand cyberknif remain healthi
particularli strong order growth emea india radixact
continu make clear contribut order growth tomotherapi
moreov regulatori licens decis onrad china announc
along result like pave way increas uptak china
lift hefti weight busi model neg side backlog
convers remain low impact higher net age-outs/cancel
recent sept quarter seen solid start year yet
see compani deliv consist quarterli perform particularli
backlog convers front continu reserv likelihood
drive meaning upsid number sub-scal player matur
capital-intens industri mind continu see better risk/reward
name coverag remain underweight
new product roadmap focus imag softwar motion correct
radixact recent highlight ctrue iter reconstruct
imag front real-tim motion sync treatment deliveri front
submit first custom instal expect
term cyberknif also recent discuss volo
optim expect doubl throughput reduc treatment
plan time deliveri time therebi catalyz replac cycl
launch kv cbct cyberknif next month addit
thought initi pleas see recent astro recap
onrad ramp china delay regulatori licens
decis recent resolv although china expect
growth driver launch onrad market remain subdu due
continu regulatori delay importantli resolv
recently-announc class a/class radiotherapi licens quota cmh
total impact remain seen timelin still remain uncertain
announc signal start believ ramp contribut
china medium term
expect product revenu growth coupl servic revenu growth
result total revenu y/i move
 guid flat due product mix heavili
skew toward tomotherapy/radixact platform bottom-lin
compani guid ebitda rang exclud
one-tim charg expect charg reflect
improv due strateg restructur initi reduc cost
noncommerci function estim annual save start
maintain underweight acknowledg solid start fiscal year
continu gross product order momentum valuat remain
compel ev/sal continu cautiou view broader
radiat oncolog market admittedli saw improv
ltm growth although sustain remain key question face
cost margin pressur new technolog halcyon
mridian ektab set least compet
dollar market although necessarili compet
system head-on mind sub-scal player matur
capex-intens industri think requir meaning invest
compet larger player limit leverag lead long-term
uncertainti continu see better risk/reward name
coverag remain underweight
question manag
aged-out order book revenu drove
dynam action take activ manag extend backlog
convers q/q
forese impact recently-announc class a/class
 radiotherapi licens quota cmh
emea india strong contributor growth america
apac rel light given dynam
expect next year
discuss benefit cyberknif volo optim
view signific enough upgrad drive replac cycl
impact would expect replac cycl
fast anticip overal market grow
look ou greatest opportun
give us updat competit landscap win rate
greenfield opportun competit replac discuss
plan drive share gain larger competit
view varian halcyon system compar
tomotherapi big competit threat
oper model cash flow
thought compani path profit
call describ strateg restructur initi reduc cost
noncommerci function share detail initi
impact expect
youv guid flat due product mix heavili skew
toward tomotherapy/radixact platform step take drive
discuss prioriti pipelin
think capit structur
thought landscap area would consid strengthen
bolt-on deal
patienc cheap valuat reward
say merger dentspli sirona form
gone accord plan would understat
combin compani face number meaning headwind past
two year mani outsid compani control includ
sustain slow dental market tie larg dso-driven price pressur
distributor signific channel disrupt caus end
pdco/siro exclus clearli self-inflict slow
pace cost synergi realiz guidanc reduct sub-optim implant strategi
seemingli reactionari move core cad/cam market exposur
faster grow di segment etc ultim led wholesal overhaul
xray leadership team current manag team casey
formerli ceo cardin health medic segment ceo nick alexo co-
founder pe firm madison dearborn partner cfo seri guidanc
cut second impair charg cours year mostli due
continu weak equip sale result inventori destock
headwind manag announc restructur plan cost one-tim
expenditur charg expect drive return top-
line growth via sbu country-level consolid greater focu big idea
innov salesforc effect invest grow market includ
china latam opm includ via reduc headcount
suppli chain integr exit unattract non-cor busi
target net annual cost save drive
doubl digit ep growth given string guidanc reset past year
expect head appear fairli conserv restructur plan
lt target help investor frame path recoveri next year
although clearli transit year manag need rebuild
credibl moreov stock ytd vs xlv
trade ntm ebitda remain ow although patienc clearli
requir compani also benefit new product bi-
annual id year restructuring-rel cost save easier comp
two year disappoint expect see steadi improv
organ growth follow string miss guidanc cut
mostli driven equip headwind result elev level
inventori destock driven dso-l price pressur among factor
although consum also declin due one-tim impact
distribut infrastructur consolid europ believ investor
expect appropri reset valuat also contract
forward ev/ebitda start year current
moreov inventori destock headwind begin abat compani
announc restructur plan kick effect new product launch
upcom bi-annu id confer march comp get materi
easier mean abl gener organ cc
lsd growth equip model coupl msd growth
consum model translat report growth number
said expect initi guid conserv
look build credibl see benefit set high bar
gate set compani solid beat-and-rais quarter
recent restructur plan long-term target posit first step
although execut key clearli struggl adapt
evolv dental market particularli transit multipl dealer
model well on-going emphasi di chair-sid cad/cam
manag unveil comprehens restructur plan call
help set compani along path recoveri plan cost
one-tim expenditur charg expect drive return consist
top-lin growth via sbu country-level consolid greater focu
big idea innov salesforc effect initi throughout
invest grow market includ china latam move
 expect opm includ via reduc
headcount suppli chain integr exit unattract non-cor
busi target net annual cost save
opm drive doubl digit ep growth turn kpi track
progress goal manag note period report
growth metric design market headcount reduct progress
target annual clinic visit nearer term compani
also benefit new product launch bi-annu id confer
march well easier comp addit end two year
destock headwind commit lower opex y/i basi
albeit cut given focu innov re-acceler
patienc clearli requir share trade ebitda
clear path recoveri place remain overweight believ
could set one interest compani
specif expect compani benefit new product
restructuring-rel cost save easier comp particularli back
half year moreov given string guidanc reset past two
year believ expect head fairli low recently-
announc restructur plan lt target help investor frame path
recoveri next year although clearli transit year
manag need rebuild credibl step back patienc
clearli requir stock ytd vs xlv
trade ntm ebitda remain ow believ risk-reward
significantli skew upsid current level especi given
broader market rotat growth valu
question manag
would character current market environ especi light
fear econom slowdown talk growth
rate see europ
need acceler market growth back msd consist
key area focu head id year
think impact id overal growth rate much lag
typic see confer pick-up growth
differ
would character competit environ cad/cam
great
penetr cad/cam market europ
prevent faster adopt cad/cam europ
see increas competit intraor scan side
see increas competit lower end chairsid mill part
market
would character relationship progress
expect
confid cad/cam imag destock longer
plan wean away depend distributor
year come
give exampl bundl opportun see
sirona dentspli portfolio
much abl rais price annual basi
gener put
give addit color imag perform past
year normal growth rate segment expect
price pressur continu
give addit color treatment center perform
past year normal growth rate segment
give addit color instrument perform
past year normal growth rate segment
big opportun valu implant segment
see opportun ration brand
talk clear align strategi
give us updat orametrix term clear align
solut well softwar platform
seen signific shift competit behavior past year
would ever consid use distributor
margin capit structur
top-down standpoint confid abl reignit
growth portfolio also cut cost
consum impact materi attempt consolid
distribut europ could see similar impact restructur
talk expect next year well driver
lower y/i opex guid
employe moral light pend cost cut see
greatest duplic headcount elabor progress made
headcount cut cut remain made
besid headcount biggest cost opportun compani
talk much invest make commerci
organ balanc need drive oper
think long-term tax rate post-merg
think share repo balanc
would character current environ
see signific opportun
see gap portfolio could potenti fill inorgan
portion busi view non-cor look
leverag ratio current target much leverag could
take right deal
bad news rearview mirror achiev
outlook remain stock
volatil value-consci tape
good year compani grappl
fallout cynosur acquisit final take write-down asset
lower outlook point elev churn sale forc
pre/post deal close follow august decis voluntarili
withdraw tempsur vitalia hand-piec probe back
market follow receipt fda letter voic concern around vagin
rejuven procedur use energy-bas devic holx monalisa
touch laser concern around molecular diagnost growth due potenti price
concess labcorp quest contract renew pama
headwind weak cytolog perinat sale due unfavor preliminari
recommend uspstf longer cervic cancer test interv
longer support co-test weak gyn surgic stagnant end market
competit novasur weigh stock brighter
note follow in-lin perform vs admittedli lower bar holx
initi outlook gener expect call organ cc growth
rang incorpor conserv assumpt cynosur
renew term lh/dgx contract addit issuanc favor
uspstf final guidelin revers draft recommend
recommend co-test sign stabil novasur light
develop holx compel valuat plu broader market rotat
growth valu stock ralli year end trend expect
continu continu view execut turnaround
stori compani work improv result cynosur gyn surgic
drive continu solid momentum breast diagnost
share trade ntm price-to-earnings believ risk-reward remain skew
upsid maintain overweight rate
tale two halv saw grappl
fallout cynosur write-down point elev churn
 sale forc pre/post deal close follow august
decis voluntarili withdraw tempsur vitalia hand-piec probe
follow receipt fda letter voic concern around vagin rejuven
use energy-bas devic holx monalisa touch laser look
ahead investor also wari headwind molecular diagnost due
upcom contract renew labcorp quest broader pama
headwind weak cytolog perinat sale due unfavor
preliminari recommend around cervic cancer test uspstf
coupl novasur declin gyn surgic despit spate bad news
manag manag stabil perform reset
expect provid initi outlook came relief given
potenti headwind mention
outlook come relief clariti follow lh/dgx contract
renew conserv assumpt around cynosur manag
initi guidanc call revenu growth cc
report point organ cc growth expect rang
declin divest blood screen segment expect balanc
continu strength breast molecular diagnost well sign
stabil novasur importantli includ quest labcorp
contract renew diagnost announc multi-year deal provid
cytolog molecular tests/instrument one note agre
term multi-year extens suppli contract
allevi investor concern around price concess well cynosur
headwind base fda letter subsequ vitalia withdraw
refunds/reb associ prior sale vitalia handpiec unus probe
tempsur system well significantli reduc monalisa touch sale
forecast also assum minim vitalia contribut despit
segment expect lsd-msd growth across board led msd
growth breast new product faxitron focal
therapeut tuck-in acquisit continu drive robust momentum
strength molecular diagnost panther panther fusion increas
util women health virolog respiratori assay drive
growth off-set continu declin divest blood screen busi
y/i declin region expect grow
lsd absorb headwind vitalia withdraw regulatori
environ intern expect grow hsd bottom line
guid ep rang oper improv
new product expect larg off-set geographi mix
cushion new share repurchas author excl deploy
maintain overweight step back believ finish
encourag note robust growth breast
diagnost along sign earli stabil novasur importantli
manag outlook come relief investor worri
impact price concess part diagnost contract renew
fallout fda letter vagin rejuven said continu
view execut stori compani work improv result
cynosur gyn surgic drive continu solid momentum breast
diagnost doubt compani build momentum
look better extens improv
even potenti msd organ growth although current model
organ share trade ntm price-to-earnings believ
risk-reward skew upsid maintain overweight rate
question manag
cyno perform obvious remain key investor focu give us
updat sale forc follow elev churn pre/post deal
light fda letter vitalia withdraw impact think
progress busi throughout year vitalia back
market
given vitalia recent reintroduc give us updat
convers fda plan gener data
discern shift competit landscap non-invas
fat reduct zeltiq continu well placement y/i
cyno/zltq note believ non-invas fat reduct
market highli under-penetrated key driver increas
latest think hospit capit spend
given lsd-msd organ growth guidanc talk differ
growth driver much contribut expect new product
term penetr tomo recent note penetr
domest market number go next year
next five year
talk current competit landscap tomo
ge siemen market talk competit
advantag feel geniu system
launch two new mammographi system last coupl year
 perform segment market target
platform
competit account trend sinc enter market
seen price pressur
view market opportun affirm prone biopsi system
similarli brevera biopsi system talk advantag
platform offer larg opportun
share updat thought faxitron focal therapeut
tuck-in fit breast portfolio
breast servic remain reliabl msd grower talk near-term
opportun segment
molecular diagnost growth continu robust primari
driver strength expect growth
especi clariti around lh/dgx renew
type impact see pama lab capit spend
inning regard panther launch
intern placement date ou
big market opportun panther fusion percentag
current instal expect adopt fusion
expect revers uspstf guidelin impact cytolog
myosur continu grow ldd sustain longer term growth rate
confid earli sign stabil novasur
seen signific improv long-term
opportun market
key intern invest prioriti
think growth skelet base sale
horizon system bone densiti human perform manag
oper model cash flow
biggest upside/downsid factor top-lin guidanc
biggest opportun drive higher next
longer term percent revenu expect spend
major opm expans lever next year
look ou process move manufactur ou take
long option buy exist manufactur facil shift product
see benefit
talk latest capit deploy prioriti
elimin convert debt target leverag ratio
talk acquisit framework deal criteria
could see execut addit deal near-term focus
integr cyno faxitron
upsid set continu ou uptak
pipelin sp ion
repres yet anoth strong year
compani handili outperform across key metric includ procedur growth
led continu robust gener surgeri intern uptak system
placement xi adopt surprisingli strong newer system provid
boost margin latter come initi expect
despit invest relat new system deploy sp ion flexibl
cathet system advanc enhanc imag intellig system
compani also continu make meaning invest global
infrastructur clinic develop expect hospit capital-expenditure
environ remain stabl procedur growth
underpin stabil dvh/dvp continu uptak emerg growth
procedur includ hernia colorect thorac expect intern
procedur growth handili outpac continu
develop ou market upsid recently-issu china quota
placement system place china far highest global util
rate pipelin perspect expect focu remain sp ramp
follow fda approv late may control launch underway
three unit ship ion flexibl cathet platform
complet submiss fda lung cancer biopsi earli septemb
underli fundament mind primari obstacl stock
continu perpetu high expect broader market rotat
growth valu regardless compani continu offer one
signific white space growth opportun healthcar along
univers continu like setup stock see deep dive
recent sage kol call debrief detail
procedur growth runway pipelin
expect continu robust procedur growth underpin
gener surgeri led hernia grow intern adopt
follow two strong year procedur growth compani
steadili increas guidanc throughout expect
repres jpme continu strong growth driven
increas adopt gener surgeri particularli hernia
colorect bariatr could also grow contributor steadi albeit
mute growth dvh/dvp volum continu traction
lobectomi thorac procedur expect intern continu
outpac expand ou footprint issuanc new
quota china novemb repres upsid estim said
expect initi procedur guid conserv could
potenti see wide rang given somewhat limit visibl number
key variabl includ time actual placement result
aforement china quota procedur growth japan follow
reimburs approv addit procedur april
cadenc sp ramp
expect repres anoth strong system year continu
healthi xi uptak sp ramp recent china quota
expect post anoth strong year system placement led
continu healthi xi uptak solid momentum sp ramp remind
continu place grow number system oper leas basi
meaning portion ultim bought custom
compani system field leas outsid
 mention view china potenti upsid driver given new
quota establish late system news articl suggest
hospit alreadi place order although visibl actual number
order placement time remain limit
pipelin progress also point healthi setup head turn
product pipelin receiv fda approv urolog procedur
sp platform late may phase launch underway three unit
ship strong feedback earli user
compani also submit transor clinic procedur addit
applic expect follow urolog transor
colorect procedur remain initi target platform although
earli discuss sever specialti well earli traction
sureform stapler also impress follow approv earlier
hundr procedur perform help drive
bariatr penetr start complex co-morbid case second-
gener cut seal instrument vessel seal also receiv posit
custom feedback second quarter launch submit
enhanc grasper hernia repair turn ion flexibl cathet
program compani note posit feedback chest confer
octob includ strong support among physician experi use
altern manag complet submiss fda earli
septemb lung potenti use case road
maintain overweight underli fundament mind primari
obstacl stock continu perpetu high expect
broader market rotat growth valu regardless compani
continu offer one signific white space growth opportun
healthcar along univers continu like setup
stock see deep dive recent sage kol call
debrief detail procedur growth runway
question manag
latest think hospit capit spend
talk recept new system receiv type
custom primari adopt
competit seem make nois verb surgic
jnj/verili titan medic well auri flex
cathet thought competit environ
besid price see competit differenti offer
consol haptic feedback etc plan respond light
start august verb launch expect
oper leas and/or usag base arrang increasingli
import talk thought process behind grow
preval arrang impact busi model
latest thought sp ramp well feedback earli
user quickli think get follow-on indic clear
latest think price sp patient cart full
expect initi procedur area interest sp transor
hernia clearli remain growth driver think size
market adopt curv
inguin hernia uptak progress better expect
primari driver
hernia need publish cost efficaci data order drive
penetr major studi watch
dvh/dvp volum came higher expect
main driver expect growth moder
drive faster adopt colorect larg opportun
clearli signific opportun procedur
countri signific near term growth opportun
new quota system place china talk
visibl term order placement time
expand reimburs place japan talk
expect placement procedur growth region
thorac continu build momentum talk primari
driver expect
discuss bariatr opportun need drive
penetr market
give latest thought flexibl cathet market opportun
expect releas addit clinic data flexibl cathet system
submit expect approv
launch flexibl cathet system econom look like
thought auriss monarch platform receiv fda
approv march view collabor ethicon
robot bronchoscop ablat creat potent competitor ion
flex cathet competit mdt super dimens platform
envis invest significantli build sale channel
ahead ion launch
advanc imag obvious key area invest compani
expect see new product segment informat
cloud capabl plan launch augment realiti offer
next coupl year light featur like offer
import meet investor pay attent
year larg scale studi investor focus
next year
oper model cash flow
gross margin profil system vs procedur vs service/train
see room gross margin improv
rel heavi sg a/r invest year talk
spend prioriti next year
expect see leverag model move past
expect launch sp flexibl cathet program impact
expect tax rate impact tax reform
latest thought share repurchas level
sinc arent pursu buyback activ talk latest
broader market acceler off-set difficult comp
varian saw mix result mostli strong top-line
better-than-expect system placement bottom line adj ep
inconsist fall short estim toward end year due tariff
headwind geograph mix heavili skew toward intern
term product halcyon placement ramp materi order
bring total order sinc launch may truebeam continu
perform well var linac instal base partli off-set proton
book new order sinc although posit news emori site
gone live astro introduc two new system bravo
probeam also provid updat long-term strategi analyst
day color see astro recap step back
encourag focu new market new product valu creation also
recogn adjac entri oper improv initi clearli take
time deliv result tariff add element uncertainti meanwhil
continu reserv long-term outlook broader radiat
oncolog market manag consid mid-single-digit market
upsid surprisingli grew vs aid
halcyon although continu look sign sustain ramp
light evolv cancer treatment paradigm hypofraction target
therapi earlier detection/liquid biopsi drive need fewer system
share trade healthi premium forward price-to-earnings appear
unwarr face volatil remain underweight
revenu order posit halcyon placement make
signific headway ep fall short tariff start impact
revenu driven combin hardwar
softwar servic full-year gross order remain strong
underpin order growth apac order growth emea
order growth north america mainli larg multi-
site order surprisingli proton revenu saw continu weak
took two proton order year
term product halcyon placement ramp materi unit
place vs bring total order sinc launch may
manag attribut recent uptick partli season
histor strongest quarter also cite fact
first full quarter clearanc well second full quarter
kv imag emea indic revenu like lumpi
note previous bigger question around halcyon much
system expand var instal base emerg market main
opportun lie halcyon order sinc launch emerg
market increment unit although expect continu
growth apac market halcyon recent receiv china nmpa approv
allow market cancer treatment system countri
year eclips licens order also come strong order
date rapidplan compani knowledge-bas treatment plan
softwar saw strong ramp particularli toward end year
regist licens order bottom line ep
year came jpme/consensu primarili due flat
impact tariff headwind bp impact total
compani level geograph mix heavili skew toward
introduc two new system year astro confer bravo
probeam bravo new hdr afterload brachytherapi ce
mark clear alreadi ship europ ship begin
next may expect drive replac cycl grow compani
brachytherapi busi revenu although note
brachytherapi util prostat cancer treatment persist
declin past year turn smaller
footprint match size competitor iba latest system new system
expect save vault construct cost case
said system sell price vault construct cost remain
high even smaller footprint proton mostli like remain nich
opportun one physician spoke note daili volum
patient requir realiz payback year
hint adapt flash therapi function pipelin
regard pipelin preview ai-driven adapt plan softwar
capabl integr multi-mod imag includ ct/pet/mr
gener adapt plan right treatment coupl minut littl
physician interact requir vs minut done manual system
initi avail halcyon due system faster imag
acquisit abil henc higher imag qualiti timelin
commerci launch unclear compani also introduc long-term
opportun around flash therapi deliv ultra-high radiat dosag
within second gy/sec current dose rate probeam preclin
data shown flash therapi work specif tumor spare healthi
tissu could offer new altern around radiotherapi toxic proven
practic said still earli day need work safeti
solut human studi conduct ultra-high dose rate
achiev probeam system competitor iba older proton system
due technolog constraint therefor although concept innov
think flash therapi like nich applic given limit
proton instal base term key accomplish year
extend compani global footprint expand address market
acquir lead local distributor taiwan open new facil brazil
develop aria ccip local softwar leverag growth china
also make channel invest fuel growth long-term also
acquir evin innov enhanc oncolog
capabl launch oncolog multidisciplinari tumor board
veloc rapidspher intervent oncolog market
var long-term strategi involv expand multi-
disciplinari cancer care softwar centerpiec strategi
analyst day also host astro note within next five
year expect extend softwar capabl surgic oncolog immune-
oncolog intervent oncolog even genom year acquir four
softwar compani alreadi mobiu humediq evin noona
annual sale manag specif highlight noona acquisit
extend compani patient data capabl patient-report
outcom real-world evid open door biopharma
clinic trial collabor road although note mani
healthcar compani also compet field hardwar side
compani note revenu opportun replac exist
global c-seri instal base truebeam halcyon time
note impli system asp vs current truebeam asp
halcyon asp think reflect expect custom price
sensit tri increas emerg market penetr time
final compani also recent announc chang execut
compens framework better align manag incent long-
term growth strategi tie manag incent plan econom
profit reward decis drive effici capit alloc
oper effici performance-specif metric includ three-year
revenu compound-annual-growth-rate ebit margin matrix reward decis fuel long-
term growth valu creation
revenu guidanc impli robust growth difficult
comp tariff add element uncertainti look
ahead manag provid guidanc call revenu growth
vs street msd move compani guid
opm vs street reflect mix tariff impact
continu sg invest support sale emerg market
bottom line guid ep vs street reflect
bottom line tariff headwind manag expect
heavili weight toward first half year variou mitig
effort around tariff kick capit deploy manag note plan
pursu tuck-in opportun align portfolio object also
continu buyback share remain exist author
provid cushion bottom line next fiscal year
maintain underweight put togeth acknowledg strong
order growth particularli halcyon continu reserv
var abil meaning sustain acceler top-lin growth
backdrop sluggish radiotherapi market admittedli saw
improv growth aid halcyon tariff
headwind like impair margin expans near-term
guidanc report impli robust growth difficult
comp although still wari long-term growth
potenti broader radiat oncolog market recogn adjac
entri oper improv initi take time implement deliv
result factor mind continu trade
healthi premium forward price-to-earnings seem unwarr face
continu volatil maintain underweight rate view
evid strong oper result includ sustain acceler
growth key construct view
question manag
provid overal thought hospit capital-expenditure market
seen expect paus hospit spend
believ radiat oncolog market growth longer term
fair say market replac market flat
equip growth forese futur softwar servic drive
growth see
think market stand term consolid clinic
seen slow market return normal
continu gain share elekta key market
discuss competit environ price trend
recent quarter elekta becom less disciplin price term
given manag turnov
emea market condit volatil past quarter
talk health market see pocket strength
continu view china signific opportun particularli given
recent china nmpa approv halcyon discuss market
plan drive higher penetr region
tariff front minim impact tariff
margin still expect impact given youv
file exempt share color talk
administr progress
percentag instal base gener replac order per year
think truebeam adopt curv mani year
left growth see
besid sr procedur use case perform truebeam
halcyon drive custom choos truebeam
much halcyon help term improv backlog convers
clearli custom need suffici patient volum realiz throughput
benefit halcyon think translat address market
halcyon
servic busi seen signific growth recent year much
room growth view revenu
book two proton order book sinc
need happen promot addit momentum step
plan take
discuss invest clinic studi prioriti rational
earli cancer detector like liquid biopsi continu gain public
becom realiti view technolog chang
landscap radiat oncolog
oper model cash flow
talk pipelin respect inorgan expans
radiolog adjac market product categori
distract attract fundament includ grow
end june tale two halv out-performance
driven steadi string beat impact cook acquisit close
octob enthusiasm around grow biolog exposur partial
off-set flat due sluggish perform softgel chang lt
outlook continu call top-lin growth manag cite
feedback investor urg conservat addit softgel weak
product particip revenu headwind perhap disappointingli
rocki start compani miss revenu ebitda
result longer-than-expect delay restor ibuprofen suppli basf
addit spate one-tim issu come period mix result
thank beinheim facil closur done decent job
string togeth seri clean beat underwhelm
perform bring back memori linger perhap structur lack
quarterli visibl busi manag admit much note
prudent focu annual rather quarterli perform said
remind investor ibuprofen suppli shortag beyond control
industry-wid issu product particip revenu headwind
well telegraph fact maintain guid suggest
upsid elsewher portfolio like within biolog start
clearli disappoint softgel headwind remain overhang
next coupl quarter re-affirmed fy outlook still achiev
see limit downsid risk given current valuat ntm ebitda
patienc like reward out-performance next month
ibuprofen shortag one-tim drive messi start
report disappoint result revenu cc
adj ebitda street/jpm due larg weaker-than-
expect softgel perform cc linger ibuprofen suppli
shortag result basf texa facil closur elimin
world suppli expectedli lower product particip revenu well
soft across bsdd cc organ due shipment time issu
respiratori ophthalm odd cc due decreas end-market demand
certain high-margin offer decreas volum fee-for-servic
develop analyt test css cc impact off-set
strong contribut cook cc bsdd growth junip
acquisit cc odd growth
cook acquisit continu exceed expect robust biolog
demand support futur growth cook contribut cc
growth bsdd third full quarter follow close deal
late octob secular shift toward larg molecul
repres drug pipelin render biolog manufactur crucial
opportun manag note expect industri demand
outstrip suppli next five year compani deriv revenu
biologics-rel activ overal exposur increas
light cook acquisit target next
month look closer cook current product commerci
approv capac util expect increas year
room materi capac expans possibl site high margin
busi gener biolog turn organ biolog effort
facil expans madison wi complet revenue/capac
expect continu ramp util third train expect
similar cook expect ramp four
year remind broke ground new sq ft
expans madison facil add third train single-us
bioreactor single-us capac expect drive bulk
futur market growth compani sign number contract
third train coupl robust funnel late stage clinic opportun
reiter plan move forward fourth fifth train madison
site also look addit capac cook site vs prior
plan one sum continu expect doubl digit
revenu ebitda growth core biolog offer
despit weak start year lead indic remain posit
guidanc still achiev despit slow start year
maintain outlook revenu ebitda solid
lead indic cook/junip contribut expect off-set
modest full-year outlook softgel specif advanc deliveri
technolog compani introduc new product
expect contribut revenu full-year css busi
ltm came backlog q/q net new
busi win increas y/i perhap importantli despit
miss remain confid prior outlook call
revenu regard softgel manag expect full-year
growth due ibuprofen shortag vs earlier
expect last anoth quarter move adj ebitda
expect impli bp margin expans
midpoint also lt ebitda growth target adj
net incom project note pro forma cook
junip debt paydown net leverag stand lend balanc
sheet flexibl continu capital-expenditure invest capital-expenditure
focus biolog
maintain overweight despit near term visibl issu start
clearli disappoint softgel headwind remain overhang
next quarter re-affirmed fy outlook still achiev
see limit downsid risk given current valuat ntm
ebitda look ahead continu believ global leader
drug deliveri outsourc market sit nexu sever favor
secular trend includ grow demand biopharma compani
complex dose form includ biolog low outsourc penetr rate
drug deliveri function rang significantli lower
cro sector expect ctlt differenti diversifi oper
platform particularli post-cook increas biolog exposur
increasingli begin find favor investor seek stabil
volatil market end-to-end solut deep regulatori expertis coupl
sticki custom relationship drive consist top-lin growth
industry-lead margin de-lever drive ep growth go
forward maintain overweight rate
question manag
expect quarterli visibl busi improv markedli
ibuprofen shortag softgel abat product particip headwind anniversari
smooth lumpi css revenu busi
come structur lower quarterli visibl vs
year plu sinc transact seen shift
competit dynam particularli within softgel post capsugel acquisit
lonza patheon acquisit
think penetr much lower compar cro
penetr admittedli data limit valu prop seem obviou
custom retic give control manufactur process especi
custom consolid pharma/gener impact
gener biosimilar entri convers over-the-counter impact margin
impact expect drug price pressur term opex cut
biopharma client manufactur cost small fraction
drug price dc could impact tighter budget
biolog gone revenu today new
custom reach today take get revenu
key inflect point watch
give us quick updat cook integr base recent
commentari sound like track plan
capac util look like madison facil
bloomington cook made decid pursu capac expans
site vs earlier plan madison
light on-going plan capac add train madison
add bloomington expect util trend
next year much increment capac alreadi spoken
watertight contract
light invest ramp new capac expect margin
look like interim
gap still left biolog portfolio
think industri capac risk industri over-
capac specif liter space next year
commerci scale manufactur biolog obvious key capabl
area interest biopharma compani well
competitor lonza patheon samsung wuxi other also
make concert push market differenti
said past pipelin current biolog
pipelin biolog go requir less capac
full commerci scale light fact pharma chosen add
larg volum capac biolog rel nich popul
hard pharma compani build smaller volum capac time
quick thought gpex biosimilar cell line traction smartag platform
updat roch collabor potenti mileston
drove decreas end market demand higher margin offer oral
drug deliveri well lower volum fee-for-servic develop
analyt test expect trend continu
share thought rational behind junip acquisit
close updat integr date
term control releas capac winchest ky facil
util stand today see trend
share updat blow-fill-s proactiv process improv
drove make improv remain done
shipment time issu impact respiratory/ophthalm volum
behind
see long term potenti steril inject busi
drove decis enter anim health market steril
inject big potenti opportun recent
big product particip revenu drug deliveri solut
today time-frame expect inflect point
term recent declin see impact carri forward
drove cut guid growth softgel
call relat ibuprofen shortag lsd growth
still feasibl turn corner issu
progress updat basf expect fulli
run texa plant guidanc assum term
return normal suppli given ibuprofen use softgel
api softgel outsiz exposur
depend singl supplier facil
shift competit dynam given strength seen
capsugel late thought recent expans plan around late stage
clinical/commerci encapsul solid oral inhal dosag form
underli strength seen accucap rel origin
expect sustain dynam go forward drive
margin differenti busi legaci softgel mix
extent have/can bridg gap
remind us busi mix prescript softgel
consumer/vm growth rate expect market
margin like across two segment
led soft volum america eu last coupl quarter
traction like consum latam apac decid
scale back china commit japan
expect product particip revenu headwind
anniversari quantifi impact term segment growth
quarterli basi
would ever consid divest softgel segment begin focu
valu ad busi drug deliveri biolog
talk strateg fit clinic suppli servic rest
portfolio
remind us impact css revenu margin
steadi state growth go forward
term core storag distribut busi vs lower margin
compar sourc see trend evolv
sustain uptick backlog net new busi win
capit structur
bp ebitda margin expans call
half driven account chang outsid investor
think margin trajectori next coupl year
softgel cost cut biolog leverag drive bulk dynam
kept top-lin lt growth target unchang
room upsid ebitda growth forecast guidanc
alreadi north rang ep growth
forecast particularli de-lev
remind us fx impact could see impact
on-going brexit tariff chatter come fruition uk
beyond biolog capac key area intern invest go
term capit structur de-lev
think beyond bolt-in sort adjac
interest
besid capital-expenditure think prioriti use
solid strong out-performance underpin robust growth
dsa includ mpi acquisit close april manufactur
support help off-set expectedli mute growth rm although even
momentum q/q acceler encourag underli market
dynam clearli trend right direct manag continu
execut key strateg prioriti capac build oper
initi effici cost save particularli within rm although
partial off-set cost associ addit personnel capac higher
wage togeth underpin forecast hsd top bottom-lin
growth step back robust earli stage demand driven biotech
 spend show sign abat signific advantag scale
continu accru larger continu like stori view
compani best-in-class preclin asset especi wil mpi
acquisit reiter overweight rate head
market fundament crl robust competit posit bode well
remain bullish preclin outsourc opportun
crl domin competit posit vs peer covanc lh
envigo privat especi wil mpi acquisit start
rm compani continu target long-term lsd organ revenu growth
adjust om term underli trend higher valu
research model disease-specif human model increas demand
china help off-set reduc demand global biopharma client
dsa continu call hsd long-term organ growth
adjust om safeti assess busi still outperform
favor market trend appear set continu manag expect
outsourc penetr rate increas today
futur final manufactur continu target ldd long-term organ growth
om busi benefit increas focu biolog
along grow demand comprehens rapid solut microbi
solut note crl leverag ratio increas flexibl
addit go forward strateg acquisit remain top prioriti
cash use follow debt paydown taken togeth ldd report growth
hsd organ om organ inorgan next five
year drive ldd ep growth
dsa remain growth driver head continu see
robust momentum discoveri servic opportun compris
medicin chemistri biolog screen adme/pk expect grow
ldd rang outsourc penetr current growth
primarili driven oncolog follow rare/orphan diseas cns/neurolog
immunology/id busi provid earli custom touchpoint
compani focus expand set client work
discoveri safeti assess current level
turn safeti assess outsourc market
outsourc figur expect eventu approach sa book
backlog remain strong legaci capac near-optim level head
mpi addit room expans importantli biotech
fund remain robust addit vc biopharma fund capit
market fund near-record level track second
highest year fund three year cash hand limit intern
 infrastructur largest player sa market share
includ wil mpi follow lh/covanc envigo
final bioanalyt servic repres opportun especi light
agilux acquisit growth hsd rang led biolog
mpi acquisit bolster dsa momentum remind close
mpi single-sit preclin cro acquisit april increas
exposur high-growth smid-cap biotech custom base addit
ad scale safeti assess mpi add ototox abus liabil
capabl expand crl exist capabl gener specialti
toxicolog includ ophthalmolog juvenil toxic molecular biolog
surgeri well medic devic test importantli mpi revenu
contribut date exceed initi expect contribut
dsa segment growth smid-cap legaci mpi client show interest
broader capabl oper methodolog larger legaci
biopharma client express interest work mpi increas client mobil
across network help accommod grow client demand
legaci capac near-optim level util mpi continu
avail capac open rel quickli avail
qualifi staff gate factor also open possibl
gener top-lin synergi road assum current forecast
mpi gener revenu expect add
crl top-lin recent trend suggest potenti upsid
rang follow term capit deploy plan
move forward manag note open addit strateg
acquisit top prioriti capit alloc focu adjac vs
enter new vertic accret addit pay debt absent
new deal continu intern invest accommod current pace
demand focu enhanc scientif capabl broaden early-
stage capabl expand capac staff invest technolog
provid critic data intern client use
manufactur support see materi upsid secular shift
biolog drug pipelin biolog test solut continu benefit
increas number larg molecul develop
manufactur biolog requir significantli analyt biosafeti
test due larger size complex product live system
market expand ldd rang growth led new biolog cell
gene stem cell therapi viral vaccin vs old biolog mab
recombin protein tradit vaccin etc see growth
driven biosimilar overal biolog market repres
opportun driven earli develop analyt support
function lot release/valid capac expans
underway across board led signific expans pennsylvania
transit certain oper malvern new site
support growth next year along ireland germani
support ou demand turn microbi solut opportun across
steril non-steril product market busi continu benefit
acquisit endosaf rapid endotoxin detect celsi rapid microbi
detect accugenix microbi id strain type given increas
market demand comprehens rapid qc solut term
growth strategi focus convert tradit user rapid detect
product manufactur effici improv cost structur enabl
better price increas focu data management/softwar solut
expand global footprint
final remain domin player within matur rm segment
share global rm market opportun
share research model market roughli one everi two
model sold world-wide compani term servic market
share term primari growth driver
research model manag continu highlight market expans
opportun china dd growth sale approach rm
fuel govern healthcar spend reform regulatori framework
pharma manufactur grow demand qualiti research model
highlight current site beij shanghai plan expans
locat road turn research servic segment greater
use specialti immunodefici model enabl innov
technolog crispr along infecti diseas diagnost
support growth gems/rad insourc solut benefit
flexibl vivarium manag lab support solut togeth growth
driver expect off-set unit volum declin global pharma client
matur market due infrastructur consolid target research drive
effici studi design new screen technolog term drive
continu om improv continu focu drive oper
effect via optim capac manag along initi around
autom inventori product manag suppli chain manag
continu deploy note rm growth came better
expect organ q/q acceler underpin acceler
biopharma research activ robust growth china along
grow demand research model matur market
maintain overweight rate overal robust earli stage demand driven
smid-cap biotech show sign abat signific advantag
scale continu accru larger continu like charl river
stori view compani best-in-class asset preclin space
maintain overweight rate head
question manag
thought continu biotech strength
sustain spend last coupl year see shift
tenor convers either smid-cap biotech european
thought recent comment fda commission scott
gottlieb develop plan address concern add signific cost
primarili via qa/qc work also limit trial access biopharma
drug price concern abat somewhat yet price increas harder
come futur expect headwind cro industri growth
result dynam
talk growth trend within research model busi term
small vs larg model well geographi sustain uptick
rm growth saw
give us updat rm pc market china
see share evolv market
talk opportun busi much
custom base within larg pharma vs biotech vs academ
talk impact niaid contract
give us updat facil closure/consolid autom
plan rm help preserv oper margin expect
near term disrupt initi
growth rate expect discoveri busi
drive discoveri client also sa work
distribut partnership enhanc discoveri capabl
sa next month outlook glp non-glp studi
give us updat capac util price trend
industri well especi light comment around
share exampl cross sell success follow integr
mpi think avail capac facil
turn manufactur support walk us trend
see among biolog custom base expect recent public
market volatil impact spend smid-cap biopharma
plan open new pa biolog facil degre
constrain segment margin
talk specif opportun driver emd/in vitro
expect hit oper margin target
manufactur support light facil transit capac
margin capit structur
walk us underli segment assumpt term
medium term target top-lin growth hsd organ ldd report
put segment margin profil togeth key lever
need deliv achiev medium term target oper
talk improv work capit made
addit enhanc could make go forward
think tax rate base revis
expect tax reform tax save oper effici
comment elong dso see result
shift toward smaller client sever cro peer brought late
talk capit deploy prioriti next year
leverag ratio
term area size target target
return hsd growth off-set margin expans
constraint full valuat
iclr strong year benefit in-lin sale growth continu
effici gain albeit slower pace robust industri backdrop although
note iclr cro mention slight plateau biotech
spend head manag lt outlook call hsd top-
line growth expect like come low end rang due
wind-down flat modest increment sg leverag result
bp opm expans y/i ldd ep growth also continu
investor focu scarciti valu asset follow sustain consolid
cro space specif lh acquir covanc chiltern
merg inventiv form quintil merg im form
parexel go privat etc suggest possibl iclr could target
merger equal transact acquir remain
posit end-market trend iclr abil continu execut
robust market backdrop believ persistently-low backlog convers
expect remain rang result mix shift toward complex
oncolog work could hamstr translat order revenu medium
term furthermor light linger question around degree/pac
smid-cap strength off-set declin near-term expect contribut
revenu go forward iclr abil drive greater-than-expect
margin expans via sg leverag increasingli competit late-stag
market includ shift toward lower-margin fix price contract current
valuat high end clinic cro peer group maintain neutral rate
wind-down well understood cadenc ramp
smid-cap biopharma work iclr top-lin growth continu
impact increment impact ad privat inventiv
part addit addit prxl privat although
renew contract three-year period possibl
extens anoth two posit expect work continu
wind repres sale backlog
manag current expect
stabil sale start vs prior expect steadi
state contribut low-to-mid teen rang iclr continu see
double-digit revenu growth among ex- custom base work
quicker burn less skew toward complex area rel rest
trial portfolio increasingli skew toward complex trial smaller
custom result constraint top-lin growth oper leverag
remain healthi backlog convers continu trend
reflect mix shift custom base net busi win drove
healthi close backlog grew
y/i order trend remain solid unclear whether backlog convers
improv persist trend lower prior quarter
vs rang earlier go
forward believ backlog convers improv like limit
secular increas trial complex iclr backlog oncolog
coupl custom mix shift toward smaller biopharma client drive
put two factor togeth believ upsid number
harder come given step backlog convers
final year overhang contract hit steadi state top line
organ growth unlik exceed rang current model q/q
margin improv trend current level also hamstrung
new clinic trial slow ramp lower-margin work grow faster
full servic contract iclr expect flat rang go
forward modest opm improv conting cut sg via
increas use robot process autom bottom line howev
cushion increment buyback although current prioriti remain
 mostli string-of-pearl approach focus tuck-in although
manag express willing consid larger deal
elev valuat constraint geograph apac/eu
therapeut orphan drug diversif repres target area
maintain neutral appreci healthi end-market trend trust
iclr abil continu execut robust market backdrop
believ persistently-low backlog convers could hamstr translat
order revenu medium-term furthermor view linger
uncertainti around whether smid-cap strength continu enough
off-set declin near-term iclr abil drive greater-than-
anticip margin expans via sg leverag competit late-stag
market coupl full valuat high end peer group
maintain neutral rate head
question iclr manag
cro call slight plateau biotech spend
head thought continu biotech
strength sustain spend last coupl year
see shift tenor convers either smid-cap biotech
european client
thought recent comment fda commission scott
gottlieb develop plan address concern add signific cost
primarili via qa/qc work also limit trial access biopharma
begin hear slowdown fund-rais due foreign
invest us compani come greater scrutini light ip theft
expect contribut revenu increas
year expect term run-rat go forward
think cadenc spend light faster
burn due less complex work
relationship evolv sinc renew contract
like extend contract anoth year
upon expiri initi period expect
drug price concern abat somewhat yet price increas harder
come futur expect headwind cro industri growth
result dynam
talk outlook sole provid relationship cro side
relic past relationship mean term
price visibl work mix margin look
like strateg vs work across portfolio
thought recent move almost peer adopt
narrow definit backlog respons lack correl
older definit metric futur revenu consid
would metric look like includ written
award look like non-pf client head
backlog convers rate undergon clear structur move lower
expect downward pressur metric next year
elabor elong dso see result
shift toward smaller client revers trend
light on-going consolid space see greater
competit smaller client and/or share shift
relat note talk trinetx watson
partnership well mapi pmg acquisit fit
broader strategi leverag big data faster trial enrol start-
time
margin capit structur
spoken past gross margin pressur offset increment
sg leverag expect dynam continu light
tight labor market stabil
much room keep lid sg drive opm
expans robot autom biggest driver dynam
thought recent consolid space feel
need add scale compet better
talk capit deploy prioriti next year term
 area size target target
would ever consid expand adjac like commerci solut
busi similar obtain via inventiv merger
cmo preclin asset
think share repurchas go forward given
best-in-class win oce momentum point
earli biopharma custom feedback q-im merger posit
cost synergi target look achiev abil drive revenu synergi via
share gain base optim clinic trial enrol process result
access im data remain key focu head particularli
custom traction date respons nextgen offer suggest
intrigu long-term potenti term sector trend stabl biopharma
budget coupl iqvia best-in-class backlog trend increas
cro penetr rate bode well compani moreov cost synergi
target continu look achiev beatabl manag highlight
despit invest enhanc platform compani continu expect
margin expans medium term remain commit grow ebitda
sale growth step back meaning top-lin impact
revenu synergi via share gain base optim clinic trial enrol
process result access im data remain show-m stori
earliest view long-term potenti encourag earli sign
success clear posit moreov financi de-lever achiev follow
im merger coupl on-going buyback plan tuck-in provid
path double-digit ep growth continu trade
discount tool cro/cdmo averag ev/ebitda basi
maintain overweight rate
outlook call msd revenu growth line current forecast
may seem underwhelm first glanc factor csm headwind
although expect busi bottom lag
extrem strong book translat growth expect
occur start difficult ta comp although oce saa offer
continu gener solid traction includ marque global win roch
expand salesforc collabor launch oct moreov current
rate fx expect pose y/i headwind compani
continu expect increment growth bp vs stand-alone quintil
net busi win saw largest ever book quarter
look extrem healthi ttm net busi win total
y/i old standard along win
repres ttm ratio vs
end contract backlog incl reimburs expens
expect convert revenu ntm basi
gen cro oce win continu demonstr potenti share
gain perhap importantli new busi win support nextgen stand
vs expect would
appli trial vs earlier contract
alreadi includ win client done little/no work
past new custom well grow traction emerg
biopharma y/i growth ytd award ebp ta side
continu highlight orchestr custom engag oce saa
offer collabor tool leverag ai/machin learn cross-
function integr client commerci oper
competit bid post launch roch global implement latest
marque win follow top-ten pharma client global implement
pharma client top-thre pharma market roll-out mid-siz
pharma client decis deploy oce countri compani also
recent expand salesforc collabor plan launch analog
offer clinic trial call orchestr clinic trial technolog
oct encompass area content manag complianc
virtual trial turn deal-rel cost synergi initi expect
achiev synergi remaind
current track achiev
scale nextgen remain top prioriti progress ahead plan iqvia
invest nextgen platform focus big data
infrastructur ai machin learn predict algorithm autom global
analyt librari data scientist strateg partnership process re-
engin enabl evidence-driven design reduc protocol
amend identif qualifi site reduc low/non-enrol
site acceler patient recruit nextgen offer
countri exit cover enrol patient faster plan
taken togeth manag expect nextgen pipelin coverag expand
initi expect
invest constrain margin growth doubl digit ep
growth still appear achiev along msd top-lin growth
continu expect ebitda growth revenu growth
compani could take share decid offer fix price contract
project goal manag growth deliv client expect
also grow margin manag reiter confid drive margin
expans although improv somewhat
constrain near term due plan invest nextgen offer
final capit deploy plan continu spend per
year share repurchas author remain
avail spend repurchas portion
recent secondari tuck-in target annual inorgan
growth contribut remain top prioriti maintain net leverag
ratio alreadi level taken togeth adjust ep
growth doubl digit rang medium term look easili achiev
reiter overweight step back top-lin impact
meaning revenu synergi via share gain remain show-m stori
view long-term potenti encourag earli sign success
record new busi win share gain via oce ta plan
launch analog oct offer next year clear posit moreov
on-going buyback plan tuck-in provid path double-
digit ep growth mind reiter overweight rate
question iqvia manag
end-market product outlook
sustain on-going strength emerg biotech fund feel like
ipo market begin cool although one
strongest year record year fund alreadi bag
thought recent comment fda commission scott
gottlieb develop plan address concern add signific cost
primarili via qa/qc work also limit trial access biopharma
begin hear slowdown fund-rais due foreign
invest us compani come greater scrutini light ip theft
differ sell dynam smaller firm segment
help off-set matur strateg partnership revenu larg pharma
take drug price rhetor come dc post-midterm
risk could see near term pipelin disrupt
repriorit base renew focu drug price
comment think outsourc penetr rate stand today
term late stage research well rwe csm segment
much room upsid time-frame
talk outlook sole provid relationship cro side
relic past relationship mean term
price visibl work mix margin look
like strateg vs work across portfolio
talk trend see competit price dynam
cro busi peer respond offer fix price
contract note fraction rfp involv price
mechan mani run cost overruns/sav
highlight gross award date numer exampl
nextgen offer posit impact clinic trial begun
see evid share gain peer penetr new account
traction emerg biopharma
beyond better/fast patient/sit identif nextgen offer
help address last mile problem patient enrol believ site
ownership confer advantag regard
drove increas nextgen pipelin coverag estim
natur ceil
key driver slowdown backlog convers rate
industri seen last month think impact top-
line growth medium term
sever cro peer acknowledg lengthen dso
custom look favor term later payment trigger point
mileston etc risk could lead non-pay collect
issu road particularli book busi skew toward
percent busi deriv smid-cap
biopharma client talk trend see biotech
spoken portfolio repriorit certain client past
see trend continu impact cancel
turn world evid help differenti offer
peer underli market growth look like segment
particularli term regulatori progress willing accept rwe
data part regulatori submiss
turn technolog analyt solut segment beyond exist
scale drive competit moat view key
competitor space
talk oce saa offer traction youv seen
market think drive competit win vs
big could roch contract term financi impact
domino effect penetr larg biopharma client
elabor strateg rational expand salesforc
collabor function expect includ orchestr
clinic trial oct offer statu quo today
hope replac
beyond tough comp factor constrain growth
turn csm clearli posit busi sale
seem decid keep hous expect csm stabil
make confid outcom especi light
prior comment around price pressur limit visibl limit
scope margin enhanc csm
decid keep csm hous would consid
acquir value-ad asset busi like commun
consult innov data-en sell solut vs contract sale
financi outlook capit deploy
number outstand havent seen translat
top-lin growth elabor dynam drive
besid structur slower backlog convers expect
book strength and/or deal synergi driven share gain translat top-lin
medium term combin busi msd growth right way
think steadi state top-lin organ growth key busi
driver could drive upside/downsid rel estim
investor think ebitda margin busi
nextgen invest coupl top-lin yet truli break
mean flattish y/i margin perform despit track ahead expect
deal cost synergi longer term low-to-mid
rang ceil room upsid
left total buy-back author still
top prioriti capit deploy think
cadenc buyback
term net leverag ratio comfort level
target debt fix vs variabl
appetit would consid deal signific
size rather continu focu tuck-in think run-rat
contribut go forward
sort capabl would look invest cro side well
im side think current valuat
best pure-play attract bioproduct market
seen strong momentum full year organ growth expect
vs last year driven organ growth direct-to-
custom portfolio filtrat chromatographi account total
sale oem protein product busi also remain healthi msd
growth overal promis bioprocess industri backdrop strong
secular tailwind sticki custom relationship continu view
best pure-play bioprocess supplier back unmatch growth profil
strong technolog leadership focus high-growth product area enhanc
value-ad partnership multipl lever margin expans along
option around inorgan growth bolt-on
reiter overweight rate pleas see initi report full color
strategi clearli set around technolog leadership extend
protein product via navigo partnership rgen overarch strategi
around build maintain technolog leadership given presenc
five larg player bioprocess market ge merck dhr/pall
chosen compet differenti technolog address
custom pain point part bioprocess workflow larger
competitor may ignor result limit head-to-head competit
typic compet one big five given product
look closer establish clear technolog leadership
filtrat chromatographi xcell atf perfus opu
prepack column recently-announc navigo partnership give
exclus ip right co-develop ligand extend leadership
protein product partnership alreadi produc ngl
impact ligand use purolit develop resin rival
best protein resin market prisma term perform
significantli lower price cheaper compani expect product
come pipelin everi month believ half
dozen proprietari ligand portfolio establish technolog
leader ligand space
filtrat expect lead growth larg increas penetr
spectrum synergi win-win partnership among three product
segment filtrat largest tam rgen market share
current leav plenti runway continu share gain
segment highest growth within y/i driven
expans atf fed-batch process current market vs
perfus strong tangenx tff traction spectrum synergi addit
growth expect acceler partnership
introduc next-gener perfusion-en bioreactor expect launch
integr rgen xcell atf control technolog srt
biostat bioreactor collabor market-expand move
lower barrier perfus adopt unifi bioreactor control
atf control single-us interfac therebi save end user time
effort also allow tap srt custom base minim
increment commerci invest also worth note partnership
non-exclus leav opportun explor similar
collabor bioreactor supplier
balanc mix clinic vs commerci stage exposur support
stabil futur growth total compani level deriv
sale clinical-stag activ commercial-stag activ
direct-to-custom product mainli filtrat chromatographi
higher clinical-stag exposur oem product mainli protein
gener serv commercial-stag applic importantli balanc
mix clinical- commercial-stag exposur provid stabil
current busi rich pipelin futur busi clinical-stag drug
move commercial-stag product
long-term financi outlook call organ compound-annual-growth-rate
opm look ahead manag expect busi sustain
organ compound-annual-growth-rate next five year ge contract expir
expect creat revenu headwind continu healthi
growth merck kgaa oem new ligand navigo/purolit
partnership robust uptak growth factor protein revenu
off-set shortfal within protein product coupl one two
medium-s acquisit revenu contribut bring
total revenu move continu
target opm driven gross margin expans target
gm expans may limit capital-expenditure invest scale manufactur
commerci leverag partial off-set stepped-up revenu
navigo partnership result opm target
 remain import growth engin support manag
strong track record acquir attract asset creat valu
deep knowledg rich experi bioprocess industri well
track record four success acquisit sinc refin atol tangenx
spectrum manag proven abil pick differenti
technolog drive toward commerci success deliv
growth acquir asset broader market growth
go forward compani technolog blueprint consist intern
develop acquire-and-upgrad done previou
reiter overweight overal remain confid compani clear
strateg direct strong competit posit sustain growth
momentum posit long-term outlook bioprocess market
continu view pure-play bioprocess supplier
technolog leadership one top smid-cap name
question manag
overview strategi
much divers set end market post spectrum
acquisit could talk outlook end market
mab vaccin gene therapi dialysi etc one present
geographi market largest growth driver
market expect largest driver go forward
what current mix cmo vs biopharma custom talk
effort move custom biopharma custom
kind invest make effort
expect multi-sit adopt key long-term growth driver much
happen alreadi think custom scale
next year
elabor opportun build servic busi big
opportun progress made
view competit landscap differenti
larger competitor talk competit
posit product line
light new navigo/purolit partnership what updat growth
outlook oem ligand busi next year
remind us much ge contract volum expect move
in-hous end next year partnership chang
convers ge/merck term exist contract
what current market share growth factor much share
expect take year
xcell atf what rate perfus adopt far see
inflect point ahead
import move fed-batch sustain lt growth
momentum xcell atf barrier atf adopt batch
process gap technolog offer need fill
achiev move
tangenx tff big opportun tangenx cassett
much revenu contribut key driver product
tfdf much revenu contribut expect
best applic technolog big opportun
spectrum integr spectrum go provid
updat progress achiev revenu cost synergi target
geograph expans new end market product cross-sel
expect new sale forc reach full product what progress
opu allow enter recombin protein vaccin market
talk current capac suppli demand market
competit dynam differ recombin protein vaccin vs mab
fast think penetr market much
market think captur
what current capac util facil expans last year
expect ramp need invest get week
lead time your target
your put focu intern talk
 pipelin prioriti
make sure maintain technolog leadership given rapid
pace innov bioprocess suppli
term futur think intern develop versu
see compani evolv long term plan go
deeper within exist offer plan extend offer
bioprocess adjac
talk strategi appetit larg
deal like spectrum character type opportun your
see term capabl interest
commerci turnaround healthi compel
transit year compani focus stabil
perform rebuild investor confid come underwhelm
period perform follow incr-inventiv merger particularli
commerci follow spate custom cancel well reduct ad
spend shaki start year mar coupl contract
modif pushout clinic strung togeth solid perform
commerci final see return growth look ahead overal
momentum busi look solid clinic ttm vs
coupl commerci ytd vs
reiter remain track achiev ttm target although
backlog convers tick q/q due largely-expect increas trial
complex plagu entir clinic cro industri importantli
note sequenti acceler driven particularli strength commerci
card reiter confid cost
synergi target note track achiev save
vs prior expect realiz
buy-back author remain also cushion bottom
line step back view return growth commerci solid
optimist comment overal posit consist quarterli
perform like renew investor focu attract fundament advantag
scale especi post-merg compel rel valuat discount
ev/ ebitda vs peer volatil market broader rotat
underway growth valu feel particularli well-posit
outperform
see acceler growth top bottom line
shaki start year mar coupl contract modif
pushout clinic strung togeth solid perform
commerci final see return growth come
relief investor follow period sustain weak busi due
custom downsiz cancel manag shi away
give specif forecast call note expect
acceler growth y/i modest acceler clinic fx start-up
delay longer ramp timelin off-set commerci
expect exceed market growth turn inventiv integr
remain confid cost synergi target revis upward
note track achiev save
higher prior target realiz combin
acceler top-lin expect margin expand meaning rel
moreov also announc share repurchas
author commenc march end later decemb
help cushion bottom line drive mid-to-high
backlog trend also point healthi momentum across
segment ttm clinic came healthi vs
net new busi award y/i translat quarterli
vs clinic backlog grew y/i
expect declin convers rate q/q vs
remind manag
attribut spike convers custom contract modif
impact long-term trend slowdown burn rate driven
increas trial size complex line broader industri trend
well synh outsiz exposur oncolog backlog also
remind investor start manag switch
conserv award recognit polici award includ start within six
month post quarter vs one year previous twelv month servic
includ award relat offer turn commerci net
award drove ytd vs
low penetr rate sustain uptick new drug
approv follow ytd also
support return consist growth importantli compani remain
track achiev ttm target manag continu encourag
investor consid commerci segment ttm basi
commun commerci see signific portion annual
award due annual budget alloc renew sell
solut award lumpi quarterli basi
return consist perform drive narrow
valuat discount rel peer remain lead player
cro space support sustain strength smid-cap biotech fund
expect continu industri consolid signific benefit scale
larger player healthi backlog trend remain believ
strateg rational inc/inventiv merger limit client overlap
complementari custom base broader offer particularli
commerci solut posit combin entiti well quickli
consolid market moreov annual cost save
coupl tax synergi de-lever drive mid-teen ep growth
medium term recent stabil commerci
segment along meaning increas award solid well
manag optimist comment sign inflect
stori consist quarterli perform like renew investor focu
attract fundament advantag scale perhap importantli
compel valuat discount ev/ ebitda vs peer
volatil market broader rotat underway growth valu
feel particularli well-posit outperform
question manag
sustain on-going strength emerg biotech fund feel like
ipo market begin cool although one
strongest year record year fund alreadi bag
thought recent comment fda commission scott
gottlieb develop plan address concern add signific cost
primarili via qa/qc work also limit trial access biopharma
within clinic elabor driver custom delay led
msd growth forecast see dynam continu
net busi win healthi convers rate
continu declin would need see feel confid
drive acceler clinic beyond msd rang line
initi expect busi time merger
shift competit dynam disrupt post-merg
underli caution clinic custom view key
drug price concern abat somewhat yet price increas harder
come futur expect headwind cro industri growth
result dynam
prospect biopharma consolid add increment layer
uncertainti outlook
talk thought process behind chang backlog definit
conserv one compar peer
give us specif exampl client cross sell traction
combin busi well inroad manag make
strateg account came via inventiv within commerci
success term sell smid-cap account came legaci
mix vs full servic work clinic segment today
see evolv medium term mean
turn commerci remind us portfolio servic
compar peer udg
ad budget trend look commun client
commerci head next year
light cancel saw broader
shift toward advertis avenu dont offer perhap
lower market spend light smaller target patient popul
particularli larg contract within sell solut
awar could drive quarterli volatil
taken togeth investor think model commerci
busi given season significantli stronger
due annual budget alloc renew inher lumpi
comment bid environ price trend commerci
recent time past call lose bid competitor due
price trend still continu isnt support view share
amongst other lumpi commodit busi
limit room margin expans
well correl new drug approv commerci revenu
growth past
highlight current commerci penetr rate
suggest long runway growth said commerci client
move insourc sale need given need technic knowledg
nuanc sale process come target biolog
turn commerci outlook underpin confid
busi turn corner grow sustain
term deal cost synergi room upsid beyond
target announc time-frame
thought competit landscap light on-going
consolid expect continu hit steadi state
fiercer competit smaller client and/or share shift
margin capit structur
beyond easi comp especi commerci underpin
confid abl acceler top-lin growth degre
start-up delay slower backlog convers fx dampen clinic growth
light acceler merger cost synergi think
ebitda margin offset need awar
given inventiv integr current underway talk
capit deploy prioriti next year
term area size target target
compani discuss report price report market close decemb
analyst certif research analyst denot ac cover report certifi multipl research
analyst primarili respons report research analyst denot ac cover within document
individu certifi respect secur issuer research analyst cover research view
express report accur reflect person view subject secur issuer part
research analyst compens directli indirectli relat specif recommend view
express research analyst report korea-bas research analyst list front cover also certifi per
kofia requir analysi made good faith view reflect opinion without undu influenc
